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81. INTRODUCTION
Human nature and unlimited access to food are a combination that causes Western people to
live in an almost constant postprandial state, i.e. the time period between food ingestion and
6-8 hours thereafter. However, most of the studies on lipoprotein metabolism have concentrated
on the postabsorptive state, in which the equilibrium between the transport and metabolism of
absorbed fat has been reached. Such studies monitor the endogenous pathway of lipid
metabolism. Studies in the postprandial state, however, take into account the metabolic steps
in both the exogenous and the endogenous pathways (Kirchmair et al. 1995).
Elevations of postprandial plasma chylomicrons in coronary patients was first reported more
than 50 years ago (Moreton 1947). In 1950, Moreton (1950) proposed a novel theory according
to which the development of atherosclerosis may directly result from recurrent alimentary
chylomicronemia due to repeated ingestion of fatty meals over a lifetime. However, interest in
postprandial studies declined after the observation that postprandial plasma triglyceride (TG)
levels correlated closely with fasting plasma TG concentrations. The classic publication of
Zilversmit (1979) in 1979 resumed interest in the field and the discovery of two forms of
apolipoprotein B (apoB), namely apoB-100 produced by the liver and apoB-48 produced by the
enterocytes, provided a basis for the proper separation of hepatic and intestinal triglyceride-rich
lipoprotein (TRL) particles (Kane et al. 1980). Since then, numerous investigators have made
an effort to unravel the complex interactions between TRL and the development of coronary
artery disease (CAD). 
Postprandial response is modulated by various factors such as fasting lipid levels, diet, genetic
factors and environmental conditions. The studies reported in this thesis address three of these
factors: Smoking, Asn291Ser polymorphism of the lipoprotein lipase (LPL) gene and type 2
diabetes mellitus, which all present risk factors for CAD. The key question is: may part of the
CAD risk caused by these factors be accounted for by excessive postprandial lipemia?
9Figure 1. 
Schematic illustration of lipoprotein metabolism: endogenous and exogenous pathways. 
CETP, cholesteryl ester transfer protein; Chylo, chylomicron; FC, free cholesterol; HDL, high density
lipoprotein; HL, hepatic lipase; HSPG, heparan sulphate proteoglycan; IDL, intermediate density lipoprotein;
LCAT, lecithin:cholesteryl acyltransferase; LDL, low density lipoprotein; LM-R, low density lipoprotein
receptor; LPL, lipoprotein lipase; LRP, LDL-receptor related protein; PUP, phopholipid transfer protein;
VLDL, very low density density lipoprotein. A, B-48, B-100, C, and E illustrate respective apolipoproteins.
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2. REVIEW OF THE LITERATURE
2.1. An overview of lipoprotein heterogeneity and metabolism
Variations in concentration and composition of plasma lipoproteins are of major importance
in the development of atherosclerosis, the leading cause of mortality in Western society. Plasma
lipoproteins can be divided into five major subclasses on the basis of the density at which they
float during ultracentrifugation. Lipoprotein subclasses are further separated by particle size,
electrical charge and apolipoprotein content. Table 1 outlines the most important features of
the major lipoprotein species; chylomicrons, very low density lipoproteins (VLDL),
intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high density
lipoproteins (HDL).
Figure 1 summarizes the exogenous and endogenous pathways of postprandial lipid
metabolism. ApoB-48 -containing particles derived from the intestine and apoB-100 -
containing particles derived from the liver compete for both the common lipolytic pathway and
common removal sites by hepatic receptors. The first metabolic step depends on the activity
of LPL, a key enzyme for the hydrolysis of chylomicrons and VLDL. Under normal conditions
the amount of LPL is sufficient and thus, intravascular lipolysis seems not to be rate-limiting
for clearance of TRL particles (Korn 1955, Olivecrona and Olivecrona 1995). In LPL-
deficiency however, massive hypertriglyceridemia ensues (Brunzell 1995). The second
metabolic step, hepatic removal of TRL remnants, however, remains saturated even in healthy
subjects up to 7 hours after an ordinary meal containing fat (Berr 1992). Postprandial TRL
metabolism substantially affects HDL metabolism and, in turn, reverse cholesterol transport.
2.2. Postprandial metabolism of triglyceride-rich lipoproteins
2.2.1. Absorption of dietary lipids and synthesis of chylomicrons
Dietary fat provides both energy as dense form and fat soluble vitamins essential for humans.
The absorption of fat in the small intestine under normal conditions is nearly complete. In the
intestinal enterocyte, the exogenous free fatty acids (FFA), monoacylglycerols and glycerol are
packaged as triglycerides together with phospholipids, cholesteryl esters and proteins to form
chylomicrons. The TG composition of the chylomicron particle varies according to the type of
fat ingested. Apolipoproteins AI (apoAI), AII (apoAII), AIV (apoAIV) and B-48 are
synthesized within the enterocyte and apolipoproteins E (apoE), CI (apoCI), CII (apoCII) and
CIII (apoCIII) are incorporated into the chylomicron particle in the circulation (Gotto et al.
1986). Both the digestion and absorption of dietary lipids and the synthesis and exocytosis of
chylomicrons have been reviewed extensively (Innerarity et al. 1996, Thomson et al. 1993).
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Chylomicrons are largest lipoprotein particles with a Svedbergs flotation index (Sf) varying
from Sf > 400 to Sf > 1000 and a particle diameter ranging from 75 to 1000 nm. Small
chylomicrons are more abundant, but the large chylomicrons carry the major part of the TG
mass. Once secreted into the circulation via the thoracic duct, large chylomicrons are rapidly
metabolized, resulting in the formation of remnant particles (Berr 1992). 
Table 1. Physical properties, lipid and apolipoprotein composition of human plasma
lipoproteins 
Chylo VLDL IDL LDL HDL
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12
Density (kg/l) <0.96 0.96-1.006 1.006-1.019 1.019-1.063 1.063-1.210
Composition (%)
  Triglycerides 86 55 23 6 5
  Phospholipids 7 18 19 22 33
  Cholesteryl esters 4 12 29 42 17
  Free cholesterol 2 7 9 8 5
  Protein 2 8 19 22 40-55
Apolipoproteins
  apoAI, AII, AIV x p p p x
  apoB-48 x p p p p
  apoB-100 p x x x p
  apoE x x x p x
  apoCI, CII, CIII x x x p x
2.2.2. Synthesis of VLDL
The liver produces VLDL particles, which supply energy for peripheral tissues during
fluctuations in the nutritional status of the individual. These hepatic TRL particles are secreted
to all Sf > 20 subfractions and hold apoB-100 as the major protein (Packard and Shepherd
1997). The biosynthesis of apoB-100 and assembly of VLDL particles have been thoroughly
reviewed (Borén et al. 1993, Gibbons and Wiggins 1995). 
In the fasting state, the fate of VLDL-derived FFA is oxidation in the tissues. On the other
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hand, during feeding, the liver continues to secrete triglycerides and these are then stored in the
adipose tissue as an energy resource. The entire process of VLDL production is dependent on
nutritional and hormonal status. The most important regulator is insulin, which directs the
metabolic flux of FFA between peripheral tissues and the liver. Fatty acids for VLDL synthesis
may be derived from at least four sources: de novo lipogenesis, hepatic TG stores, FFA derived
from lipoproteins taken up directly by the liver, or the plasma FFA pool (Lewis 1997). VLDL
production is not only regulated by the availability of FFA, and thus by the concentration of TG
in hepatocytes but also by the production rate of apoB-100 and the availability of phospholipids
and cholesteryl esters (Frayn 1998). 
Hepatic TRL particles contribute to postprandial lipemia (Cohn et al. 1988a, Cohn et al. 1989,
Schneeman et al. 1993). After a fat-rich meal, LPL-mediated hydrolysis of chylomicrons and
VLDL produces FFA. Limited muscle and adipose tissue uptake of FFA directs its flux to the
liver (Brunzell et al. 1973, Coppack et al. 1992). As the substrate concentration in the liver
increases, the most abundant TRLs secreted in the postprandial state are large, TG-rich particles
in the VLDL1 fraction. Besides increased particle size, postprandial lipemia induces
compositional changes in VLDL as demonstrated by Björkegren et al. (1997). Both Sf 60-400
(large) and Sf 20-60 (small) VLDL particles isolated 2 hours after fat load contained more
apoE, apoC-I and cholesterol molecules and fewer apoC-II molecules per particle than VLDL
obtained during fasting from both normolipidemic and hypertriglyceridemic subjects. However,
it is uncertain if apoB-100 secretion increases during postprandial lipemia as suggested by
kinetic data (Cohn et al. 1990), or if the delayed removal of hepatic VLDL particles from
plasma causes increases in apoB-100 concentration (Björkegren et al. 1996).
2.2.3. Intravascular metabolism of triglyceride-rich lipoproteins
Lipoprotein lipase, abundant in muscle, myocardium and adipose tissue, is anchored to the
heparan sulphate proteoglycans (HSPG) at the luminal side of the capillaries. Besides bound
LPL, a fraction of mostly inactive LPL monomers and some active LPL dimers is associated
with circulating lipoprotein particles (Felts et al. 1975, Peterson et al. 1985). A recent study
(Zambon et al. 1996) demonstrated that in pre- and postheparin samples, after inhibition of ex
vivo lipolytic activity, most of the lipoprotein lipase dimers were associated with VLDL
particles. This suggests that LPL may affect the receptor-mediated removal of these particles.
The rate of lipolysis depends on amounts of LPL, the attachment of the enzyme to the
endothelium, composition of the lipoproteins and their particle size (Goldberg 1996). The
activity of plasma LPL is closely regulated by nutritional status and increases after a meal
containing fat (Karpe et al. 1998b, Peterson, et al. 1985). Concentrations of FFA in plasma
control LPL activity under physiological conditions by substrate inhibition (Karpe et al. 1992).
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TRL hydrolysis is enhanced by the presence of apoCII, a co-factor of LPL (LaRosa et al. 1970).
Larger chylomicron particles appear to be more efficiently hydrolyzed than smaller VLDL
particles, which may partly depend on a greater probability that the larger particles will come
into contact with LPL.
Intravascular hydrolysis of chylomicrons and VLDL by LPL produces remnant particles. The
detachment of the particle from LPL -heparan sulphate complex is thought to occur after loss
of apoCII. The FFA released from chylomicron and VLDL particles by LPL action are either
used for hepatic lipoprotein synthesis or used/stored by peripheral tissues. Approximately half
of the FFA released enters the plasma FFA pool (Hultin et al. 1996) and binds to serum
albumin for transport to the liver. In the liver the flux of FFA partly determines the secretion
rate of VLDL particles. The other half of FFAs enter the adipocytes for TG synthesis and
storage. This process is regulated by insulin and acylation-stimulating protein (ASP). ASP
activity increases postprandially in the presence of chylomicrons (Cianflone et al. 1989, Saleh
et al. 1998, Scantlebury et al. 1998). If ASP activation fails to occur, as suggested in familial
combined hyperlipidemia, the plasma FFA concentrations increase and inhibit LPL activity,
which may impair lipolysis of postprandial TRL (Castro Cabezas et al. 1993, Castro Cabezas
et al. 1994, Sniderman and Cianflone 1997). 
2.2.4. Hepatic removal of chylomicron and VLDL remnants
Formation of chylomicron and VLDL remnants requires detachment of these particles from
LPL after at least 70% hydrolysis of TG content. Termination of lipolysis is probably mediated
by the detachment of apoC-II, a co-factor for LPL. Besides lipolysis, exchange of core lipids
and apolipoproteins between other lipoprotein species influences formation of a remnant
particle. The core of the particle becomes more enriched with cholesteryl esters and devoid of
free cholesterol, apoAs and apoCs (Cooper 1997). The single molecule of either apoB-48 or
apoB-100 remains an essential part of this particle. The principal feature of a remnant particle
is its ability to interact with hepatic receptors. However, a prerequisite for this interaction is an
abundance of apoE, as demonstrated by Sherill, Innerarity and Mahley (1980). The affinity of
apoE isoforms to the hepatic receptors differs; apoE-3 and E-4 isoforms possess greater
affinities than apoE-2 (Weisgraber et al. 1982). 
Hepatic receptors mediate the endocytosis of remnant particles but the initial rapid binding of
these particles to the hepatocellular surface occurs via HSPG (Ji et al. 1993). According to the
secretion-capture model of remnant lipoprotein clearance, hepatocytes secrete apoE into the
space of Disse, where the remnants attached to HSPG acquire apoE, a ligand for receptor-
mediated lipoprotein clearance (Ji et al. 1994a, Linton et al. 1998). Recently, HSPG´s role in
remnant clearance has expanded; HSPG can mediate lipoprotein binding independently from
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LRP, and therefore function in a way similar to the remnant receptors (Fuki et al. 1997, Mahley
and Ji 1999). Other enhancers of rapid remnant binding include hepatic lipase (HL) and LPL.
HL facilitates the remnant uptake process independently from the catalytic activity of the
enzyme (Daggy and Bensadoun 1986, Dichek et al. 1998, Ji et al. 1994b, Shafi et al. 1994).
LPL, besides being critical for TRL hydrolysis, is also involved in the cellular uptake of TRL
remnants. The role of LPL in this process was first suggested by Felts et al. (1975) and later
confirmed by others (Beisiegel et al. 1991, Skottova et al. 1995). In vivo evidence has recently
emerged from studies on transgenic mice showing that inactive LPL can mediate VLDL
removal from plasma (Merkel et al. 1998).
The essential role of the liver in remnant clearance was established by Redgrave (1970), who
showed that chylomicron remnants accumulate in hepatectomized rats. Later, the accumulation
of VLDL remnants in eviscerated rats was also shown (Mjos et al. 1975). Together, these
studies provided evidence that TRL remnants are primarily removed in the liver. A number of
studies have since elucidated the nature of hepatic receptors involved in remnant clearance. The
LDL-receptor is responsible for removal of LDL particles via apoB-100 but this receptor also
binds apoE (Brown and Goldstein 1986, Mahley and Innerarity 1983). Herz et al. (1988)
characterized another route for hepatic remnant clearance involving the LDL receptor-related
protein (LRP), which binds apoE and lacks affinity for apoB-100 (Beisiegel et al. 1989).
Furthermore, the binding of apoE is enhanced by LPL (Beisiegel, et al. 1991). 
ApoB-100-containing VLDL remnants are primarily metabolized through the LDL-receptor
pathway (Veniant et al. 1998). The physiological significance of LDL-receptor and LRP for
chylomicron remnant removal is controversial. The importance of the LDL receptor in humans
is suggested to be limited because normal clearance of postprandial lipoproteins occurs in
subjects with familial hypercholesterolemia (Rubinsztein et al. 1990, Weintraub et al. 1987b)
and in subjects with varying expression of the LDL-receptor (Eriksson et al. 1991). In these
subjects remnant particles do not accumulate, which indicates that a major proportion of
remnants can be cleared by LRP. However, recent contrasting data in homozygous subjects
with familial hypercholesterolemia suggested accumulation of postprandial apoB-48 particles
(Mamo et al. 1998). Evidence for the combined role of both LDL-receptor and LRP on remnant
clearance was demonstrated in a study with normal and LDL-receptor deficient mice. With the
inactivation of LRP by receptor-associated protein, remnant particles accumulated markedly
in LDL-receptor deficient mice and to a lesser extent in control mice (Willnow et al. 1994).
Subsequent data supporting the combined role of the two receptors has arisen from mice
lacking LDL-receptor or apoE or both (Ishibashi et al. 1994, Ishibashi et al. 1996), from mice
treated with inhibitors of several cell surface molecules (De Faria et al. 1996) and from mice
synthesizing apoB-48 only or apoB-100 only (Veniant, et al. 1998). Recently, Cooper (1997)
and Mahley and Ji (1999) have thoroughly reviewed hepatic removal of chylomicron and
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VLDL remnants.
2.2.5. Uptake of triglyceride-rich lipoproteins by extrahepatic tissues
Initially, chylomicron and VLDL particles are too large to penetrate the space of Disse, and
these particles may, besides being hydrolyzed by LPL and taken up by the liver, incur other
metabolic fates. These fates include the VLDL-receptor pathway and margination to the
vascular endothelium. One demonstration of the latter has arisen from a study by Karpe et al.
(1997b), in which no conversion of chylomicron particles from the Sf 60-400 to the Sf 20-60
fraction could be detected. This study suggested that the formation of small chylomicron
remnants from the larger chylomicrons and their remnant species is limited and that large
chylomicrons and their remnants are not evenly distributed in plasma but rather show signs of
being marginated to the vascular endothelium. Chylomicrons labeled with [14C] oleic acid to
trace the fate of TG and with [3H] retinol to trace the fate of core lipids have been shown to be
distributed in an apparent volume 10-15% larger than the blood volume. This provides further
evidence for margination of chylomicrons (Hultin, et al. 1996). This process may enable the
contact of chylomicrons and endothelium-bound LPL, but also impede measurements of the
true concentration of these particles in plasma samples.
Another mechanism for the direct removal of TRL is the VLDL-receptor pathway. This
receptor is located mainly in the heart, skeletal muscle and adipose tissue and can bind VLDL
and chylomicron remnants in the presence of apoE or LPL (Niemeier et al. 1996, Takahashi et
al. 1992). The physiological significance of this receptor is largely unknown. In summary, a
part of large chylomicron and VLDL particles are most likely metabolized via extrahepatic
routes. However, the hepatic uptake discussed in the previous section appears to be the
principal site of chylomicron and VLDL remnant removal. 
2.3. High density lipoprotein metabolism during postprandial lipemia
The HDL fraction is responsible for reverse cholesterol transport and is therefore anti-
atherogenic in nature (Fielding and Fielding 1995, Miller and Miller 1975). After a fat load, in
normolipidemic subjects HDL cholesterol concentration usually remains unchanged (Cohen
and Grundy 1992, Groot and Scheek 1984, Kashyap et al. 1982, Tall et al. 1982) or decreases
slightly (De Bruin et al. 1991). However, HDL composition changes profoundly as lipids and
apolipoproteins are exchanged between HDL and TRL particles. This exchange enriches the
HDL fraction with TG and decreases its apoA-I concentration (Cohn et al. 1988b, De Bruin,
et al. 1991). Individuals with high-level postprandial lipemia exhibit a decrease of the large
HDL2 subfraction and an increase in the HDL3 subfraction but little or no change occurred in
subjects with lower degrees of postprandial lipemia and high fasting concentrations of HDL2
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(Patsch et al. 1984).
Plasma HDL subpopulations arise at least partly through lipid transfer reactions mediated by
transfer proteins and enzymes. These include cholesteryl ester transfer protein (CETP),
lecithin:cholesteryl acyltransferase (LCAT), hepatic lipase and phospholipid transfer protein
(PLTP) (Navab et al. 1998). CETP catalyzes the exchange of neutral lipids, particularly TG and
cholesteryl esters, between all major lipoprotein classes. In the postprandial state, in
normolipidemic subjects, cholesteryl ester transfer has been shown to remain unchanged
(Lassel et al. 1998, Lottenberg et al. 1996) or increase (Castro and Fielding 1985, Fielding et
al. 1995). The latter arises partly from an increase in the concentration of acceptor particles,
from redistribution of CETP, from increase in CETP activity and probably also from an
increase in CETP mass (Tall et al. 1986). LCAT is essential in maintaining the unesterified
cholesterol concentration gradient between cell membranes and plasma HDL in reverse
cholesterol transport (Bruce and Tall 1995). This active TG/cholesteryl ester exchange may
initiate a remodeling of HDL, eventually resulting in the formation of pre-β-HDL which is the
initial acceptor of free cholesterol released from the cell surface (Fielding and Fielding
1995).Two possible functions of PLTP in lipoprotein metabolism have been proposed. First,
PLTP may act in the transfer of surface fragments formed during lipolysis of TRL, to HDL
(Tall et al. 1985). Second, PLTP may act in HDL conversion (Jauhiainen et al. 1993, Tu et al.
1993). However, postprandial changes in lipid transfer reactions and their significance for
development of CAD have not been studied in detail.
2.4. Determinants of postprandial lipemia
2.4.1. Gene polymorphisms
Inherited causes for chylomicronemia syndrome include familial LPL deficiency, familial
apoC-II deficiency and familial inhibitor to LPL (Brunzell 1995). Homozygous LPL
deficiencies reduce LPL catalytic activity and lead to chylomicronemia of varying severity both
in fasting and in postprandial state. Over 60 mutations in the LPL gene can cause deficiency
of this enzyme; interestingly, up to 7% of whites are heterozygous carriers (Brunzell 1995,
Murthy et al. 1996). The fasting lipid profile and postheparin LPL activity of these carriers may
appear normal. After an oral fat load, carriers of various LPL mutations have displayed delayed
clearance of TRL particles due to saturation of lipolytic capacity (Gerdes et al. 1997, Julien et
al. 1999, Miesenböck et al. 1993, Pimstone et al. 1996, Sprecher et al. 1991). Mutations in the
LPL gene seem important in development of CAD. Benlian et al. (1996) followed 4 patients
with missense mutations on both alleles of the LPL gene over a period of 14 to 30 years. They
reported coronary or peripheral atherosclerosis or both in each patient before the age of 55. In
addition, heterozygote carriers most likely possess an increased risk for CAD (Benlian, et al.
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1996, Goldberg 1996, Jemaa et al. 1995, Kastelein et al. 1998, Nordestgaard et al. 1999,
Peacock et al. 1992, Wittrup et al. 1997). In line with this, a recent study on a large cohort of
patients with CAD and healthy controls showed significant reduction in LPL activity in CAD
patients, which was associated with high fasting plasma TG and low HDL cholesterol
concentrations. The quartile of CAD patients with the lowest LPL activity had more than
double frequencies of LPL Asn291Ser and Asp9Asn gene variants (Henderson et al. 1999).
The apoE gene is the most extensively studied candidate for explaining the large inter-
individual variations in postprandial lipid metabolism. Remnant particles accumulate in
patients who lack apoE (Schaefer et al. 1986), which indicates the detrimental role of apoE in
TRL clearance. E2-allele, both in heterozygous and homozygous carriers, predisposes to
postprandial accumulation of remnant particles, since this apoE-isoform has reduced affinity
for hepatic receptors (Brenninkmeijer et al. 1987). On the other hand, also carriers of E4-allele
are suggested to display increased apoB-48 and apoB-100 responses to a fat load (Bergeron and
Havel 1996) although contradictory data exists (Boerwinkle et al. 1994, Weintraub et al.
1987a). The apoE genotype causes great variations in TRL levels and risk for CAD (Kuusi et
al. 1989, Wilson et al. 1996), hence, it must be considered in any postprandial study.
Polymorphisms in the apoB gene may partly account for variations in postprandial responses
(Byrne et al. 1996, Peacock et al. 1995). In the presence of Val591Ala polymorphism Peacock
et al. (1995) demonstrated increases in both apoB-48 and apoB-100 particles in the Sf 20-60
fraction. Conversely, the SP-24 allele was associated with decreased area under curve (AUC)
for TRL particles in the Sf 60-400 fraction. Other apolipoprotein mutations include apoA-IV
gene (Ostos et al. 1998) and apoA-I deficiency, in which TG and retinyl esters accumulate
postprandially (Ng et al. 1995). ApoC-III inhibits the hepatic uptake of TRL and therefore
reduces the catabolism of TRL particles (Windler and Havel 1985). Interestingly, deficiency
of this apolipoprotein decreases the postprandial response. In mice, homozygous apoC-III gene
deficiency reduces fasting TG concentrations and provides protection from postprandial
increase of TG concentration (Maeda et al. 1994). Other genetic polymorphisms accounting for
variations in postprandial lipemia include fatty acid-binding protein gene (Ågren et al. 1998)
and HL gene (Jansen et al. 1999).
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2.4.2. Fasting lipid and lipoprotein concentrations
There is a well known relationship between fasting plasma TG concentrations and the
magnitude of postprandial lipemia (Cohn, et al. 1988b, Denborough 1963, O'Meara et al. 1992,
Ooi et al. 1992, Redgrave and Carlson 1979). This most likely reflects the competition that
occurs between chylomicrons and elevated levels of endogenous VLDL for hydrolysis by LPL
in peripheral tissues, the so called common saturable pathway (Brunzell, et al. 1973) and for
hepatic clearance.
Previous studies have shown an inverse correlation between postprandial lipemia and HDL
cholesterol concentration (Cohn, et al. 1988b, Kashyap et al. 1983) although contradictory data
exist (Cohen and Grundy 1992, Cohen et al. 1991). This relationship is largely accounted for
by the HDL2 subfraction (Patsch et al. 1983). The observed association led to the suggestion
that low levels of HDL might not be atherogenic per se but as formulated by Patsch et al.
(1992), HDL cholesterol concentrations may represent a “memory box” reflecting postprandial
TRL metabolism. According to this theory, exchange of cholesteryl esters for TG renders the
HDL particle as a favorable substrate for HL, the enzymatic action of which produces small
dense HDL particles.
2.4.3. Insulin sensitivity 
A key feature of the insulin resistance syndrome is dyslipidemia with high TG and low HDL
cholesterol concentrations, which is commonly associated with postprandial lipemia. An early
study linking insulin resistance to postprandial lipemia demonstrated that in insulin resistant
subjects, FFA suppression, both in basal and in insulin-stimulated states, is incomplete. Besides
leading to fasting hypertriglyceridemia, this defect was suggested to have important
consequences on metabolism of postprandial TG (Baynes et al. 1991). Schrezenmeir et al.
(1993) studied TG responses of healthy men after an oral fat load and found that subjects with
excessive postprandial lipemia display high fasting insulin levels. Jeppesen et al. (1995) were
the first to demonstrate postprandial lipemia in insulin resistance measured by the clamp-
technique. In healthy, non-diabetic subjects the steady state plasma glucose during insulin
infusion was independently associated with postprandial TG and retinyl palmitate
concentrations. Postprandial lipemia declines when insulin sensitivity is improved by
metformin administration (Weintraub et al. 1998). Metabolic defects leading to postprandial
lipemia in insulin resistant states include: impaired FFA metabolism (Groop et al. 1989),
saturation of TRL remnant removal and disruption of regulation of hepatic VLDL production
(Frayn et al. 1996). Recent kinetic data by Malmström et al. (1997a, 1997b) have provided
evidence that acute hyperinsulinemia suppresses hepatic VLDL1 apoB production in healthy
men but not in subjects with type 2 diabetes.
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2.4.4. Body composition, age and exercise
Obesity, especially accumulation of visceral fat, is associated with postprandial lipemia even
in normolipidemic subjects (Couillard et al. 1998, Lewis et al. 1990, Mekki et al. 1999, Ryu
et al. 1994, Taira et al. 1999). The basic defect is probably decreased insulin sensitivity in
adipose tissue and liver, the major sites of TG metabolism. Fisher et al. (1993) found in obese
subjects an increased number of postprandial VLDL1 and to lesser extent VLDL2 particles,
which, when compared with subjects of normal weight, had similar composition. The
overproduction of VLDL1 particles may be explained by the effects of insulin resistance on
hepatic VLDL production as discussed above. In adipose tissue, obesity leads to impaired
lipolysis of postprandial TRL triglycerides (Potts et al. 1995) and impaired suppression of FFA
release (Coppack, et al. 1992, Roust and Jensen 1993).
Fasting and postprandial plasma TG concentrations increase with ageing. The first indication
that the chylomicron count after a fat load is higher in older as compared with younger subjects
was made during the1940´s (Becker et al. 1949) and has since been confirmed in more detailed
studies (Cohn, et al. 1988b, Krasinski et al. 1990b). Aging has been suggested to lead to
prolonged residence time of chylomicron remnants (Cohn, et al. 1988b) and also to increased
VLDL production rate (Millar et al. 1995).
Postprandial response to a fat-containing meal is reduced after vigorous exercise (Schlierf et
al. 1987). Regular physical exercise is associated with less than average responses of
postprandial TG (Altekruse and Wilmore 1973, Hartung et al. 1993, Merril et al. 1989).
Training appears to be protective against postprandial lipemia induced by 3 weeks of daily
alcohol intake (Hartung, et al. 1993). In normolipidemic male runners, who usually ran 30-40
miles/week, an increase in postprandial retinyl ester response was observed after 14-22 days
of lack of exercise compared with the trained state (Mankowitz et al. 1992). In physically
inactive subjects the beneficial effects of exercise on postprandial lipemia are not
straightforward as shown by rehabilitation of CAD patients, whose postprandial response to
a fat load revealed no improvement (Yanes et al. 1989). Similarly, previously sedentary middle-
aged women were compared with an inactive control group and no change in postprandial TG
peak or TG area response was noted after 12 weeks of brisk walking (Aldred et al. 1995).
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2.4.5. Diet and alcohol
Major dietary influence on postprandial response depends on the amount of fat ingested, which
modifies this response in a dose-dependent manner (Dubois et al. 1994). However, the type of
fat may have long-term or acute effects on the postprandial lipemia. 
The effect of long-term background diet composition on postprandial lipemia is a debated
issue. The polyunsaturated fatty acids (PUFA) to saturated fatty acids (SFA) ratio in the
background diet had no influence on postprandial response (Kashyap, et al. 1983, Salomaa et
al. 1993) but one study reported accumulation of hepatic TRL after a diet rich in SFA
(Bergeron and Havel 1995). On the other hand, comparing PUFA diet with SFA diet, Demaker
et al. (1991) detected lower apoB-48 concentrations after a fat load. Different vegetable
(canola, corn or olive) oils in the diet had similar effects on the postprandial TG levels
(Lichtenstein et al. 1993). A diet rich in fish oils containing ω-3 PUFA, however, appears to
reduce postprandial lipemia, most probably through decreased VLDL production rate or
increased LPL action. A study by Weintraub et al. (1988) detected a higher retinyl palmitate
response after a SFA diet compared with ω-6 PUFA and especially to ω-3 PUFA diets.
Furthermore, the in vitro lipolysis rate of chylomicrons containing ω-3 PUFA and especially
ω-6 PUFA was higher than that of chylomicrons containing SFA. The well-known beneficial
effects of Mediterranean-type diets, which are rich in monounsaturated fatty acids (MUFA),
may partly be accounted for by smaller postprandial TG and apoB-48 responses compared with
the SFA diet (Zampelas et al. 1998).
Acutely, vegetable oil and natural dairy fat in a single meal influence the postprandial response
only marginally. This is the case at least when using different vegetable oils (De Bruin et al.
1993) and different proportions of MUFA and SFA in the meal (Roche et al. 1998). However,
fish-oils reduce postprandial TG response to a single fat load, with a concomitant increase in
LPL activity (Zampelas et al. 1994). 
Epidemiological studies demonstrate that moderate alcohol consumption is associated with a
reduced risk of developing CAD. Part of this beneficial effect is explained by elevation of
fasting HDL cholesterol concentration (Chick 1998). Effects of an oral fat load combined with
alcohol-containing drinks on postprandial HDL composition have been conflicting
(Franceschini et al. 1988, Hendriks et al. 1998, Veenstra et al. 1990). Furthermore, compared
with administration of fat only, simultaneous ingestion of ethanol and fat produces additive
effects on postprandial plasma TG levels (Superko 1992, Talbott and Keating 1962, Wilson et
al. 1970). Therefore, favorable effects of moderate alcohol consumption appear not to be
mediated through postprandial TG or HDL metabolism.  
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2.4.6. Drugs and hormones
The fibrate group of drugs activate peroxisome proliferator-activated receptors, which leads to
increased synthesis of LPL, reduced synthesis of VLDL and accelerated VLDL clearance
(Kesäniemi and Grundy 1984, Staels et al. 1998). Fibrate therapy reduces plasma TG levels by
50-70% and raises plasma HDL cholesterol levels by 10-30% indicating potentially beneficial
effects on the postprandial lipid response. Weintraub et al. have reported favorable effects of
fibrate therapy on postprandial lipemia in patients with type IV hyperlipidemia (Weintraub, et
al. 1987b), in patients with isolated low HDL cholesterol (Weintraub et al. 1995) and in
patients with hypertriglyceridemia (Weintraub, et al. 1998). After fenofibrate therapy, TG AUC
in chylomicron fraction decreased in CAD patients and healthy subjects but retinyl palmitate
response remained unchanged. This was interpreted as depending on unaffected TRL remnant
removal by the liver and on a 20% increase of LPL activity by fenofibrate therapy and hence,
enhanced lipolysis of TG from chylomicron particles (Simpson et al. 1990). In type 2 diabetic
subjects with mild hypertriglyceridemia, gemfibrozil reduced postprandial TRL response
compared with placebo (Syvänne et al. 1993). Fibrates appear efficient in diminishing
postprandial lipemia and future angiographic studies may clarify their relevance in CAD
patients with high levels of postprandial TRL.
Statins inhibit hydroxymethylglutaryl-CoA reductase, the rate-limiting enzyme of cholesterol
synthesis. These drugs have been shown to be efficient in reducing postprandial lipemia in
dyslipidemic patients (Cabezas et al. 1993, Simo et al. 1993, Weintraub et al. 1989) but in
subjects with normal lipid values no effect was observed (Weintraub, et al. 1989). Possible
mechanisms include improved TRL clearance via LDL receptor and lowering of VLDL levels
and therefore, reduced competition for common removal mechanisms.
Drugs affecting fasting lipid or lipoprotein levels potentially alter postprandial lipid
metabolism. However, only a few agents have been studied. A nicotinic acid analogue
acipimox lowers TG response after an oral fat load (Pazzucconi et al. 1993). Metoprolol
increases fasting and postprandial VLDL and VLDL remnant concentrations (Boquist et al.
1998). In at least hypercholesterolemic patients, cholestyramine increases postprandial TG and
retinyl palmitate responses (Weintraub, et al. 1987b).
Estrogens influence lipid and lipoprotein metabolism by multiple mechanisms, including up-
regulation of LDL-receptors (Nathan and Chaudhuri 1997). Involvement of this receptor in the
hepatic uptake of TRL particles is consistent with a recent study on postmenopausal estrogen-
replacement therapy, which improved clearance of plasma retinyl palmitate after an oral fat
load (Westerveld et al. 1995). The same investigators also established that estrogen-
replacement therapy reduced the postprandial decrease in HDL cholesterol concentration by
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66% (Westerveld et al. 1996).
Little or no data exists on effects of adrenal cortex hormones and glucagon on postprandial
lipids. Growth hormone stimulates VLDL secretion, and on the other hand, up-regulates LDL-
receptors (Angelin and Rudling 1994). The effects of growth hormone on postprandial lipid
metabolism are largely unknown but a study in hypopituitary patients revealed a higher plasma
TG area under the curve in women with growth hormone deficiency compared with control
subjects (Al-Shoumer et al. 1997).
2.5. Postprandial lipemia and the risk for coronary artery disease
2.5.1. Epidemiological and case-control studies 
The first studies on CAD patients compared with healthy controls provided evidence for
enhanced lipemic response (Denborough 1963, Harlan and Beischer 1962, Moreton 1947).
Twenty years ago Zilversmit (1979) presented evidence that the postprandial period may
aggravate atherosclerotic process, and thereafter a number of investigations have suggested that
postprandial TRL particles play a role in development of CAD. However, the mechanisms of
atherogenicity have remained open. Discrepancy regarding association between postprandial
lipemia and atherosclerosis arise partly from heterogeneity and varying methodology in these
studies. Measurement of plasma lipid concentrations does not reveal the complex metabolic
alterations in the postprandial state and therefore, some recent studies have determined
concentrations of apoB-48 and apoB-100 particles to separate intestinal and hepatic TRL.
Besides epidemiological and case-control studies, understanding of this complex issue would
require further prospective studies. 
A number of angiographic case-control studies have indicated delayed TRL clearance in non-
diabetic CAD patients. Patsch et al. (1992) showed by multivariate analysis that plasma TG
concentrations 6 and 8 hours after a fat load provided a means for selecting CAD cases from
healthy controls. The model, including HDL2 concentration, apoB concentration and age,
classified 82% of the subjects correctly. This finding has later been confirmed (Nikkilä et al.
1994). The use of vitamin A to label intestinal TRL particles detected high concentrations of
retinyl palmitate together with increased TG concentration in the chylomicron fraction 8-24
hours after oral fat load in CAD patients (Groot et al. 1991, Simpson, et al. 1990). Syvänne et
al. (1994a) demonstrated delayed clearance of TG and retinyl palmitate from the Sf 60-400
(VLDL1) fraction in patients with CAD. This study found similarly enhanced postprandial
lipemia in CAD patients with and without type 2 diabetes. Weintraub et al. (1996) enrolled
each normolipemic subject undergoing coronary angiography under three years and measured
the postprandial response to an oral fat load. Compared with subjects with <20% coronary
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stenosis, they demonstrated clearly increased chylomicron retinyl palmitate AUC in cases with
CAD. Only few studies have measured the contribution of intestinal and hepatic particles by
quantifying apoB-48 and apoB-100 concentrations. A study of CAD patients, hospital controls
and workforce controls employed postprandial apoB-48 to apoB-100 ratio in Sf > 60 fraction,
which associated independently with the presence of CAD (Simons et al. 1987). The first
angiographic study measuring apoB-48 and apoB-100 concentrations demonstrated that
postprandial apoB-48 concentration in Sf 20-60 fraction was associated with angiographic
progression of coronary lesions over five years (Karpe et al. 1994). Together, these studies
indicate that small chylomicron remnant particles are implicated in development and
progression of CAD. However, lately a study suggested postprandial dyslipidemia in CAD to
be due to a failure of regulation of endogenous TRL species (Karpe et al. 1999).
Recent studies have investigated the association between postprandial lipemia and the early
stages of atherosclerotic disease to avoid potential selection bias related to retrospective case-
control studies. In patients with newly diagnosed exercise-induced myocardial ischemia
compared with subjects with negative exercise tests, the postprandial TG and retinyl palmitate
responses correlated with the presence of CAD in men with BMI<30, but not in women. After
adding fasting TG to the model, however, the odds-ratios became insignificant also among men
(Ginsberg et al. 1995). Intima-media thickness of the common carotid artery, a marker for early
atherosclerotic disease, was associated with postprandial responses of TG, apoB-48 and apoB-
100 in males from a random population sample (Karpe et al. 1998a). In these middle-aged men,
the intima-media thickness correlated with 6-hour plasma TG concentration independently of
fasting plasma TG or LDL cholesterol levels. In accordance, another study found a strong
association between peak postprandial TG concentration and intima-media thickness in men
who displayed mild hypercholesterolemia but no symptoms of cerebrovascular disease (Ryu
et al. 1992). These studies suggest that postprandial TRL contribute to the development of
atherosclerosis in early asymptomatic stages.
Fasting concentrations of plasma TG may represent a more important risk factor for CAD in
women than in men. A meta-analysis suggested 37% increase in CAD risk in women per 1-
mmol/L increase in plasma TG (Austin et al. 1998). Since fasting TG concentration constitutes
a strong determinant for postprandial lipemia, one could expect that postprandial TRL
contribute to the risk of CAD among women to at least the same extent as among men.
Postprandial studies in women with CAD are few in number. An angiographic study on CAD
patients included women but no subgroup analysis of their postprandial response (Weintraub,
et al. 1996). As mentioned earlier, in women with newly diagnosed ischemia, TG and retinyl
palmitate responses were similar to those of control subjects (Ginsberg, et al. 1995). Meyer et
al. (1996) compared 12 normolipidemic women with angiographic signs of coronary heart
disease with individually matched controls; they found in CAD patients higher HL activities
24
and increased fasting and postprandial apoB-48 concentrations in the IDL fraction. The data
suggested that TRL remnants are important as a risk factor for CAD in women. 
Studies on the offspring of coronary patients provide information of genetic risk for CAD. Sons
of coronary patients compared with control subjects exhibited elevated postprandial plasma TG
but not retinyl palmitate concentrations (Uiterwaal et al. 1994). In contrast, a recent study found
similar postprandial TG and retinyl palmitate responses in the male offspring of parents with
early CAD and control subjects (Slyper et al. 1998). There is an obvious need for further
studies.
2.5.2. The atherogenic remnant hypothesis
Accumulation of chylomicron remnants after an oral fat load have been observed in patients
with dysbetalipoproteinemia (type III hyperlipidemia), a condition associated with high
incidence of premature CAD (Hazzard and Bierman 1976). Furthermore, in apoE knockout
mice, the massive excess of remnant lipoproteins in plasma coincides with susceptibility to
atherosclerotic lesions (Plump et al. 1992). Are TRL remnants directly atherogenic, i.e. are they
capable of entering the arterial wall, will they be retained within arterial intima and are they
taken up by macrophages? Scepticism regarding the involvement of TRL in atherosclerosis has
largely been based on the lack of accumulation of TG in the atherosclerotic plaque. 
Size determines the atherogenic properties of a lipoprotein particle by two manners. The
smaller the particle the easier it enters the vascular endothelium but also exits the intima more
easily than the larger particles. Experimental in vivo evidence suggests that upon entrance into
the arterial intima, IDL and VLDL are trapped at least to the same extent as LDL (Nordestgaard
et al. 1992, Nordestgaard et al. 1995). When apoB-containing lipoproteins were isolated from
human atherosclerotic plaques, VLDL and IDL fractions accounted for more than one-third of
the total apoB-associated cholesterol (Rapp et al. 1994). Furthermore, the larger the particle,
the easier it is assumed to be retained within the vascular wall (Nordestgaard, et al. 1995),
although VLDL particles greater than 75 nm are excluded from entering the intima
(Nordestgaard and Zilversmit 1988). VLDL and IDL particles may directly be taken into the
intima by macrophages, foam cells and some smooth muscle cells (Gianturco et al. 1982,
Gianturco et al. 1988, Gianturco et al. 1998, Hiltunen et al. 1998, Ylä-Herttuala et al. 1991).
Large chylomicrons, like large VLDL particles, appear not to enter the arterial wall in diabetic
hypercholesterolemic rabbits (Nordestgaard and Zilversmit 1988). Nevertheless, the intestinal
TRL remnants are found in the arterial tissue (Mamo and Wheeler 1994, Proctor and Mamo
1998). Recently, Cianturco et al. (1998) demonstrated a TRL receptor which specifically binds
apoB-48 or its apoB-100 equivalent in human monocyte-macrophages. The receptor-mediated
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uptake of TRLs could provide essential nutrients or, in hypertriglyceridemia, cause foam cell
formation (Gianturco, et al. 1988, Gianturco, et al. 1998). The arterial retention of chylomicron
remnants is consistent with Zilversmit´s hypothesis that atherogenesis is a postprandial
phenomenon (Zilversmit 1979, Zilversmit 1995).
2.5.3. Effect of postprandial lipemia on hemostasis and endothelial function
Hypertriglyceridemia presents a procoagulant state, which may partly account for the CAD risk.
Activation of Factor VII, a risk marker for CAD, occurs postprandially (Miller et al. 1996,
Sanders et al. 1999, Silveira et al. 1994). Large postprandial TRL particles appear to activate
coagulation factor VII through the intrinsic coagulation pathway (Silveira et al. 1996).
Postprandial lipemia increases also concentrations and activity of plasminogen activator
inhibitor, indicating impaired fibrinolysis (Byrne et al. 1998).
Endothelium-dependent relaxation of coronary arteries is impaired in patients with CAD.
Recent studies suggest altered endothelial function in hypertriglyceridemia (Lewis et al. 1999)
and after a fat load (Plotnick et al. 1997, Vogel et al. 1997) although one study detected no
effect (Williams et al. 1999). Furthermore, perfusion of isolated rat (Grieve et al. 1998) or
rabbit aorta (Doi et al. 1998) with chylomicron remnants resulted in the impairment of
endothelial function. Thus, impaired endothelial function and alterations in the coagulation
cascade may present additional mechanisms by which TRL remnants can have an impact on
atherosclerosis.
 
2.6. Smoking and lipid metabolism
Smoking is linked with proatherogenic alterations in several lipoprotein fractions and lipid
transfer protein activities in the fasting state. Craig et al. (1989) summarized the changes in a
meta-analysis by showing a dose-dependent increase in total, LDL and VLDL cholesterol and
in total and VLDL TG together with decreases in HDL cholesterol and apoA-1. The
disturbances in lipid metabolism are similar to those seen in insulin resistance syndrome, a
condition associated with smoking (Eliasson et al. 1994, Facchini et al. 1992, Rimm et al.
1995). Constant adrenergic stimulation by nicotine is presumed to partly explain metabolic
abnormalities in smokers (Creyer et al. 1976). Smokers also exhibit increased levels of growth
hormone (Attvall et al. 1993) and adrenal androgens (Hautanen and Adlercreutz 1993).
Adipose tissue LPL, which is the rate limiting enzyme for uptake and storage of TG-derived
fatty acids by the adipocyte, seems to be regulated differently in smokers compared with non-
smoking subjects (Brunzell et al. 1980, Chajek-Shaul et al. 1990). The postheparin LPL activity
is a combined measure of both adipose tissue and muscle LPL activities, and therefore may be
of limited significance in smokers. Evidence of enhanced FFA supply to the liver, indicating
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increased lipolysis via adrenergic stimulation, exists in smokers (Andersson et al. 1993, Creyer,
et al. 1976, Hellerstein et al. 1994, Kershbaum et al. 1968). High levels of especially VLDL TG
are explained by the increased substrate input into the liver, as discussed earlier. Elevated TG
concentrations commonly predispose to increased prevalence of small dense LDL particles, a
condition also noted in smokers with (Griffin et al. 1994) and without CAD (Eliasson et al.
1997). 
Both dyslipidemia with high TG/low HDL concentrations and insulin resistant states are
associated with postprandial lipemia and therefore abnormalities in postprandial TRL
metabolism might occur in smokers. So far, only a few reports have studied postprandial
plasma lipoprotein metabolism in smokers, and these studies have not included separations of
TRL subfractions (Axelsen et al. 1995, Eliasson, et al. 1997, Elkeles et al. 1983).
Recent studies show that dyslipidemia associated with smoking can be modified by genetic
polymorphisms including the platelet glycoprotein aIII gene (Senti et al. 1998) and the CETP
gene (Dullaart et al. 1998).
2.7. Type 2 diabetes mellitus and postprandial lipemia
As early as 1917, Allen (1917), basing his studies on partly depancreatized (diabetic) dogs,
stated that “the most striking experiment is to keep the plasma continuously clear by
carbohydrate or protein diet, then suddenly give a meal of fat. High lipemia is present within
a few hours and persists for more than twenty-four hours.” Based on animal studies and
observations on diabetic patients he further pointed out that diabetic lipemia is both higher and
longer lasting than lipemia under non-diabetic conditions. Kallio (1967) presented in his thesis
that males with diabetic hereditary display enhanced and prolonged alimentary lipemia closely
resembling the responses of diabetic and coronary patients. These early observations are still
valid in type 2 diabetic subjects. 
Later, postprandial lipemia was demonstrated to present an inherent feature of diabetic
dyslipidemia (Cavallero et al. 1994, Chen et al. 1993, Lewis et al. 1991, Syvänne, et al. 1994a).
These studies have detected increased TG and retinyl ester concentrations in plasma and in
chylomicron and VLDL fractions. Determination of apoB-48 levels was performed in one
study, which, in line with the previous ones, found an increased apoB-48 response in the TRL
fraction (Curtin et al. 1994). Together, these studies imply impaired metabolism of intestinal
TRL particles in type 2 diabetes. However, no data on postprandial apoB-100 concentrations
in the type 2 diabetic patient exist.
The mechanisms underlying fat intolerance in type 2 diabetic subjects are not fully clear.
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Previous studies suggest a combined effect of both increased VLDL1 production in the liver
and competition of chylomicron remnants and VLDL remnants for the common removal
mechanisms. Malmström et al. (1997a) demonstrated recently that suppression of hepatic
VLDL1 apoB production by insulin is impaired in type 2 diabetes, resulting in inappropriate
release of VLDL1 particles. Furthermore, adipose tissue of type 2 diabetic patients is resistant
to the normal suppression of FFA release by insulin, which increases the input of VLDL
substrate to the liver (Chen et al. 1987, Swislocki et al. 1987). On the other hand, in the
postprandial phase, the sudden increase in both apoB-48 and apoB-100 particles competing for
limited LPL activity and restricted number of common binding sites in the liver may saturate
TRL metabolism for hours (Coppack 1997). In type 2 diabetes, LPL activity is decreased and,
hence, this pathway may be more easily saturated contributing to the delay of TRL clearance
(Brunzell et al. 1975, Nikkilä et al. 1977). As further evidence for the lipolytic defect, diabetic
patients lack the normal inverse correlation between postprandial lipemia and postheparin LPL
activity (Syvänne, et al. 1994a). Other potential factors impairing TRL metabolism in diabetic
subjects include glycation of apolipoproteins, especially of apoE (Curtiss and Witztum 1985,
Mamo et al. 1990), and accelerated rate of cholesteryl ester transfer (Bagdade et al. 1993). 
2.8. Methods for studying postprandial TRL metabolism
Intestinal apoB-48 particles reside in Sf > 12 fractions. These particles are removed from the
circulation before reaching the size close to LDL and thus, apoB-48 is generally not found in
the LDL fraction. ApoB-100 particles, on the other hand, constitute a wide range of
lipoproteins from very small LDL to large VLDL particles. Because of overlapping size and
chemical composition between each other and other lipoprotein species, the basic difficulty in
separation of TRL particles is that they are indistinguishable by ultracentrifugation.
To circumvent these problems, several clinical studies on postprandial lipid metabolism have
utilized vitamin A to trace intestinal chylomicrons and their remnants. The background for this
is that vitamin A is incorporated into these particles as retinyl esters, mainly retinyl palmitate,
which remain with the chylomicron particle throughout its metabolism (Goodman 1980) and
are rather simple to quantify. This method, however, possesses a number of limitations. Firstly,
it does not allow measurement of the hepatic apoB-100 particles, secondly, intestinal
absorption of vitamin A is variable (Hollander 1981), thirdly, postprandial retinyl ester
response does not necessarily parallel that of TG (Krasinski et al. 1990a) and apoB-48 (Karpe
et al. 1995), fourthly, retinyl esters are found in apoB-100 particles especially in the late
postprandial period (Cohn et al. 1993) and finally, different concentrations of retinyl esters have
been detected in larger chylomicrons compared with smaller ones (Karpe, et al. 1995).
A more exact estimation of the relative contribution of hepatic and intestinal lipoproteins in
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TRL fractions can be obtained by specific quantitation of apoB-48 and apoB-100. A number
of groups have reported the use of sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) developed for this purpose (Karpe and Hamsten 1994, Kotite et al. 1995, Poapst
et al. 1987, Zilversmit and Shea 1989). SDS-PAGE is sensitive for overloading protein but
linear concentration curves and equal chromogenicities of apoB-48 and apoB-100 are achieved
by using smaller amounts of protein (Karpe, et al. 1995, Zilversmit and Shea 1989). 
ApoB-48 consists of 48% of the N-terminal amino acid sequence of that of apoB-100. Raising
specific antibody against apoB-48, however, has been successful. An ELISA method with
specific antibody allows measurement of very low concentrations of apoB-48 in whole plasma
apparently without cross-reactivity with apoB-100 (Lovegrove et al. 1996, Peel et al. 1992).
When compared with SDS-PAGE, the correlation was r = 0.74 in a series of postprandial
samples of 12 subjects (Lovegrove, et al. 1996).
The stable isotope technique has been applied to study postprandial apoB-100 kinetics
(Björkegren, et al. 1997). This procedure describes both production and catabolism phases, but
difficulties arise from non-steady state kinetics and measurement of apoB-48.
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3. AIMS OF THE STUDY
Patients within the present studies comprise smokers, carriers of LPL Asn291Ser gene variant
and subjects with type 2 diabetes. Each of these conditions increases the risk for CAD
substantially. Furthermore, a major proportion of this risk is explained by changes of plasma
lipid and lipoprotein concentrations. The hypothesis of these studies is that part of the risk for
atherosclerosis in these three conditions is accounted for by abnormalities of TRL metabolism
in the postprandial state.
Lipoprotein particles enriched with triglycerides after a fat load have varying properties and
different metabolic fates. Therefore, we aimed to determine the specific contributions of
various subfractions of apoB-containing lipoproteins to postprandial lipemia.
The specific aims of this study were to answer the following questions:
Are the postprandial responses of TG, retinyl ester, apoB-48 or apoB-100 modified by the lipid
composition of an oral fat load in healthy, normolipidemic men? Does the lipid composition
of an oral fat load influence postprandial responses of cholesterol, TG or apoE in the HDL
fraction? 
Are healthy smokers lipid intolerant as compared with non-smoking subjects with similar
fasting lipid profile, apoE-phenotype and body composition? May the postprandial increase of
plasma TG be accounted for by apoB-48 or apoB-100 particles, or both?
Is the postprandial increase in TRL particles in smokers related to postprandial changes in HDL
or apoE metabolism or in lipid transfer protein activities?
Does the LPL Asn291Ser gene variant modulate postprandial lipemia in TRL or HDL fractions
in carriers with normal insulin sensitivity and fasting lipid concentrations?
Is the severity of coronary atherosclerosis determined by angiography related to the magnitude
of postprandial apoB-48 or apoB-100 response in type 2 diabetic subjects?
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4. SUBJECTS
Each subject enrolled in these studies gave his/her informed consent. The Ethics Committee
of Helsinki University Central Hospital endorsed the research protocols. Table 2 outlines the
subject characteristics.
Table 2. Characteristics of the study groups
Control
Subjects1
Smokers LPL A291S Type 2
diabetics
Number of subjects 22 12 10 43
Males/Females (n) 17/5 12/0 5/5 31/12
Age (years) 38 ± 2 40 ± 2 38 ± 5 57 ± 1*
BMI (kg/m2) 23.9 ± 0.5 25.0 ± 1.0 23.5 ± 0.9 29.8 ± 0.5*
Glucose (mmol/l) 4.5 ± 0.1 4.4 ± 0.2 5.2 ± 0.2* 9.0 ± 0.3*
Insulin (mU/l) 5.7 ± 0.5 6.0 ± 0.8 5.7 ± 0.6 --
C-peptide (nmol/l) 0.51 ± 0.04 0.68 ± 0.06 0.76 ± 0.13* --
Smokers (n) 0 12 0 7
1 Combined from studies II and IV
Data are number of subjects or mean ± SE.
*p < 0.05 compared with control subjects
Study I. Study I comprised ten healthy non-smoking volunteers. Each received three oral fat
loads: a mixed meal, a cream meal and a soybean oil meal and had a heparin test to measure
lipase activities. All subjects had normal BMI and used no medications. Thyroid, renal and
liver diseases were excluded by routine laboratory tests. The subjects were selected to have
apolipoprotein E phenotype 3/3. None consumed a special diet and the amount of reported
physical activity (3.1 ± 0.6 hours/week), and alcohol consumption (5.1 ± 1.4 drinks/week) were
moderate.
Studies II and III. To study the effect of habitual smoking on postprandial TRL and HDL
metabolism, 12 male habitual cigarette smokers participated in an oral fat load and heparin test.
All were healthy, had no medication and thyroid, renal and liver diseases were excluded by
routine laboratory tests. Subjects from Study I and two additional subjects with corresponding
characteristics formed the control group. The two groups were selected to have similar fasting
TG and HDL cholesterol concentrations. In addition, age, BMI, waist-hip-ratio, lifestyle and
both fasting glucose and insulin were comparable between smokers and control subjects.
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Study IV. Ten previously identified carriers of Asn291Ser polymorphism in the LPL gene with
normal concentrations of fasting plasma lipids and glucose were included in Study IV. Each
carrier was individually selected to have a normolipidemic non-carrier control subject with
comparable age, sex, BMI and apoE phenotype. The subjects underwent an oral fat load, an
euglycemic hyperinsulinemic clamp study and a heparin test. Each carrier and control subject
was healthy, non-obese and used no medications. Each subject was interviewed by the same
investigator about lifestyle factors; none consumed a special diet and the amount of physical
activity and alcohol consumption were recorded. Thyroid, renal and liver diseases were
excluded by routine laboratory tests.
Study V. A subset of 43 type 2 diabetic patients enrolled in the Diabetes Atherosclerosis
Intervention Study (DAIS) were recruited to Study V. The protocol and eligibity criteria are
described elsewhere in detail (Steiner 1996). Each subject (31 men and 12 women) who
completed both a coronary angiography and an oral fat load at baseline were included in this
study. The subjects were divided into two groups with either severe CAD or mild CAD.
Eighteen subjects had undergone coronary by-pass surgery or angioplasty. They were all
included in the group with severe CAD but because of the preceding revascularization
procedure their severest stenosis could not be quantified in the study angiograms. Nine subjects
with no previous coronary procedures were included in the severe CAD group on the basis of
one or more stenoses in the study angiogram that narrowed the lumen diameter by at least 50%.
Thus, the group defined as having severe CAD comprised 27 subjects, 23 males and 4 females.
The remaining 16 patients (8 males and 8 females) were defined as having mild CAD because
each had at least one detectable coronary lesion, although not exceeding 50% diameter stenosis.
In patients who had not undergone a revascularization procedure, severity of CAD was defined
as the maximal per cent diameter stenosis in any major coronary brand. The clinical
characteristics of the groups with mild and severe CAD are shown in Table 3. The groups with
mild and severe CAD displayed similar age, BMI, waist-hip ratio, fasting blood glucose, blood
pressure, duration of hypertension, number of current and ex-smokers and alcohol intake. The
difference in apoE phenotype distribution was of borderline significance, p = 0.058. The
number of males and females was uneven between the groups. The group with mild CAD had
a longer history of diabetes and higher concentration of glycosylated HbA1c. Microalbuminuria
occurred equally commonly in both groups (p = 0.787). Fasting lipid and lipoprotein values are
illustrated in Table 4. In both groups concentrations of plasma TG were elevated due to
increased VLDL1 TG concentration and concentrations of LDL and HDL cholesterol did not
differ statistically. Both LPL and hepatic lipase activities in postheparin plasma were similar
between the groups.
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Table 3. Characteristics of type 2 diabetic patients with severe and mild CAD
Severe CAD Mild CAD p
Males / Females, n 23 / 4 8 / 8  0.013    
Age, years 57.7 ± 1.1 56.6 ± 1.1 0.505
Duration of diabetes, years 7 ± 1 11 ± 2 0.040
Body mass index, kg/m2 29.4 ± 0.5 30.3 ± 0.8 0.309
Waist-hip ratio 0.98 ± 0.01 0.94 ± 0.02 0.074
Apo E phenotype, n (%) 0.058
     3/3 19 (70) 8 (50)
     2/4 -- 2 (12.5)
     3/4 8 (30) 4 (25)
     4/4 -- 2 (12.5)
Systolic BP, mm Hg 135 ± 3 137 ± 5 0.930
Diastolic BP, mm Hg 84 ± 1 80 ± 2 0.139
Smokers, (Current/Ex/Never, n) 4/15/8 3/5/8 0.288
Alcohol intake, drinks/week 3.3 ± 0.7 2.7 ± 1.0 0.338
Fasting glucose, mmol/l 8.6 ± 0.4 9.7 ± 0.6 0.100
Glycosylated Hb A1c, % 7.4 ± 0.2 8.4 ± 0.3 0.007
Insulin therapy, n (%) 6 (22) 8 (50) 0.060
Use of diuretics,  n (%) 3 (11) 1 (6) 0.596
Use of β-blockers,  n (%) 19 (70) 6 (38) 0.035
Data are number of subjects or mean ± SE.
Groups were compared by Mann Whitney´s test and Chi square test.
5. METHODS
5.1. Oral fat load
Study I The subjects underwent three various fat loads containing of 63 grams of fat each. The
mixed meal consisted of bread, butter, cheese, sliced sausage, a boiled egg, fresh paprika,
soured whole milk, orange juice and coffee. The fatty acids of the meal included 65% SFA,
30% MUFA and 5% PUFA. The liquid meal with mostly saturated fat was prepared from
whipping cream and a fresh egg yolk with 69% SFA, 28% MUFA and 4% PUFA. The soybean-
oil meal contained soybean oil, glucose, egg white protein and dried egg yolk in liquid form.
The fatty acids of the meal consisted mainly of PUFA (59%) and MUFA (26%). Each meal
included 150 000 IU of vitamin A to label the intestinal chylomicrons. Subjects were asked to
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avoid alcohol intake for three days before each visit. After a 12 hour fast, an indwelling catheter
was placed in a forearm vein at 7.30 a.m. and the test meal was consumed within 10 minutes.
Blood samples were drawn before and at 3, 4, 6 and 8 hours after the fat load. After the test
meal the participants were allowed to take nothing except water until the last sample. Venous
blood was collected into tubes containing EDTA and plasma was separated within 20 minutes
by low-speed centrifugation. Samples were protected from light and kept at +4 °C before and
after centrifugation.
Studies II, III and IV A fat load identical to the mixed meal in Study I was served to the
subjects. Venous blood was collected at the same sampling times, except for Study IV, in which
the sampling times were before and 3, 6, 9 and 12 hours after the fat load.
Study V The subjects remained fasting for 12 hours before the fat load, they were advised to
refrain from alcohol intake for three days prior to testing and also to refrain from smoking for
the 12 hour fasting period. All regular medication, including hypoglycemic agents were allowed
the evening before. A glass of orange juice was allowed as an evening snack for subjects on
insulin treatment. The morning medication was taken together with the fat load test. Other
medications were allowed at their usual times. After drawing the fasting blood sample from an
indwelling catheter placed in an antecubital vein the subjects received an oral fat load in liquid
form. The mixture containing soybean oil (50 g/m2), glucose (50 g/m2), egg white protein (25
g/m2), dried egg yolk (6.3 g/m2) and water (200 mL) was prepared with lemon flavoring. To this
100 000 IU of vitamin A (Retinyl Palmitate, Leiras Oy, Turku, Finland) was added.
Postprandial blood samples were drawn 4, 6 and 8 hours after the fat load.
5.2. Quantitative coronary angiography
All coronary angiograms of type 2 diabetic subjects were analyzed using a computer-assisted
quantitative system (QCA-CMS, Medis, Nuenen, the Netherlands). The protocol is described
in detail elsewhere (McLaughlin and Gladstone 1998).
5.3. Density gradient ultracentrifugation
The density of plasma samples was adjusted to d = 1.10 kg/L with NaCl and preservatives
(aprotinin 50 IU/ mL and phenylmethylsulfonyl fluoride 1 mmol/L) were added. Four mL of
plasma were placed in 13.4 mL tube (Ultra-Clear, Beckman Inc., Palo Alto, CA) and
overlayered carefully with 3.0 mL of d = 1.065 kg/L and d = 1.020 kg/L and 2.8 mL d = 1.006
kg/L NaCl solutions. Ultracentrifugation was performed in a SW40 Ti swinging bucket rotor
at 40 000 rpm at +15 °C in a Beckman Optima LC ultracentrifuge. The Sf > 400 fraction
representing chylomicrons was isolated after a run of 32 minutes and collected by aspirating
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the top fraction of 1.0 mL. The tube was refilled with d = 1.006 kg/L NaCl solution. Thereafter,
ultracentrifugation was continued under the same conditions and the Sf 60-400 fraction
(VLDL1) was isolated after a run of 3 h 28 min. The sample was aspirated and the tube refilled
as previously. To separate the Sf 20-60 lipoproteins (VLDL2) and intermediate density
lipoproteins (IDL, Sf 12-20), ultracentrifugation was continued for 17 h and the fractions were
separated as described in detail by Karpe and Hamsten (1994). Low density lipoproteins (LDL,
Sf 0-12) and high density lipoproteins were recovered from the same tube by aspiration, and
the final concentrations were corrected with a dilution coefficient. Aliquots of the isolated
fractions were frozen immediately at -80 °C for subsequent determination of apoB-48, apoB-
100, TG, cholesterol and retinyl ester concentration.
Figure 2. 
A standard curve for SDS-polyacrylamide
gel electrophoresis. Purified
apolipoprotein B- 100 is used as standard.
Absorbance is expressed as area under the
curve (AUC) (absorbance units * min) of
the apoB- 100 band as a function of the
standard apoB-100 mass.
5.4. Separation of apolipoprotein B-48 and B-100 by SDS-polyacrylamide gel
electrophoresis
Concentrations of apoB-48 and apoB-100 were analyzed in samples obtained in density
gradient ultracentrifugation. Delipidated aliquots of samples were dissolved in buffer and run
in 3.5 to 20% sodium dodecyl sulphate polyacrylamide gel electrophoresis according to the
method of Karpe and Hamsten (1994) with slight modifications. Highly concentrated fasting
LDL apoB-100 was used as a standard. Six standard samples ranging from 0.125 to 0.75 µg of
apoB-100 were included in each run. An example of a standard curve is presented in Figure 2.
Gels were stained with Coomassie blue G-250 for at least four hours and destained in an
aqueous solution of 7% acetic acid and 12% methanol for 24 hours. Scanning of gels was
performed with a computer-assisted laser scanning densitometer (Image Quant 3.19, Molecular
Dynamics 1991, Sunnyvale, CA) at 595 nm. Peaks representing apoB-48 and apoB-100 were
integrated automatically from the image of the sample after manual removal of background
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intensity. The measurement was expressed as AUC. Concentrations of apoB-48 and apoB-100
were calculated from AUC´s with the standard curve. Control samples used for apoB-48 and
apoB-100 variability determinations were prepared from non-fasting plasma from a healthy
subject with the apoE2/3 phenotype. Plasma was separated by ultracentrifugation as described.
Fractions with Sf > 60 were pooled and delipidated. A volume of 5 µl was applied into each
lane of a SDS-gel to measure the intragel variability. To control the intergel variation, one
control sample was included with each gel. Intragel and intergel coefficients of variation (CV)
for apoB-48 ranged between 3.3- 3.7% and 13.1-13.7% and for apoB-100 2.9-3.1% and 10.5-
11.0%, respectively. The detection limit for apoB-48 and apoB-100 varied from 0.01 to 0.02
mg/L.
5.5. Assay of plasma CETP, PLTP and LCAT activity levels using exogenous substrate
assays 
LDL or HDL used as substrates in CETP and PLTP assays in Study III were isolated by
ultracentrifugation from plasma collected from healthy blood donors at densities of 1.019 < d
<1.063 and 1.063 < d < 1.210 g/ mL, respectively. The isolated lipoproteins were reisolated at
the same density and dialysed extensively against 10 mmol/L Tris-HCl, pH 7.4 containing 150
mmol/L NaCl, 1 mmol/L EDTA and 0.1 g/L NaN3. LDL was labeled with cholesteryl(1-
14C)oleate (Amersham, Arlington Heights, IL) with the lipid dispersion technique of Morton
and Zilversmit (1981). The labeled LDL was reisolated by density gradient ultracentrifugation
(Redgrave et al. 1975).
Plasma CETP activity levels were analyzed as described (Van Tol et al. 1997) after removal of
endogenous VLDL+LDL. The CETP activity measured with this method strongly correlates
with CETP mass (Hannuksela et al. 1992). Plasma PLTP activity levels were assayed using a
phospholipid vesicles-HDL system. This method is specific for PLTP activity and the
phospholipid transfer promoting properties of CETP do not interfere with the assay (Damen et
al. 1982, Speijer et al. 1991, Van Tol, et al. 1997). LCAT activity levels were determined using
excess exogenous substrate, consisting of heat-inactivated plasma containing [3H]-cholesterol
(Glomset and Wright 1964). Incubation time was 6 hours at 37bC. After extraction, free and
esterified cholesterol were separated on silica columns and [3H]cholesterylesters were eluted
with hexane (Streyrer and Kostner 1988). The activities are expressed in arbitrary units, relative
to the activity in a human plasma pool (% reference plasma).
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5.6. Assay of plasma cholesterol esterification and phospholipid transfer with endogenous
lipoproteins
The esterification rates of cholesterol were measured in total plasma as previously described
(Channon et al. 1990, Streyrer and Kostner 1988). Activities are expressed in nmol/mL/h.
Phospholipid transfer was measured according to Lagrost et al. (1996) with the following
modifications: [3H]phosphatidylcholine-labeled liposomes were added to 15 µL of plasma and
incubated for 10 min, in order to limit the transfer to values < 10% and measure initial rates.
The incubation mixture was the following: 125 nmoles of phospholipid as liposome vesicles
and 120 nmoles of iodoacetic acid (LCAT inhibitor) were mixed in 65 µL of Tris-buffered
saline (10 mmol/L Tris-HCl pH 7.4, 154 mmol/L NaCl, 1 mmol/L EDTA, 0.2 g/L Na-azide).
After incubation at 37bC, the incubation mixture was diluted to 320 µl with 240 µL of cold
Tris-buffered saline and kept on ice. Subsequently, the liposomes and apoB-containing
lipoproteins were precipitated by addition of 240 µL of a solution containing 500 mmol/L
NaCl, 215 mmol/L MnCl2 and 4.7 105 U/L heparin. The transfer of radioactive phospholipids
to endogenous HDL was measured by counting the supernatant obtained after low-speed
centrifugation. Activities are expressed as % transfer.
5.7. Determination of plasma postheparin lipase activities and LPL mass
An intravenous bolus injection of heparin (100 IU per kg of body weight) was given to the
subjects at least one week apart from oral fat load. Blood samples were drawn before and 15
minutes after the heparin injection into prechilled lithium-heparin tubes. Plasma was separated
immediately at +4 °C and stored at -80 °C. Plasma LPL and HL activities were measured from
preheparin and 15-minute postheparin samples with the method of Huttunen et al. (1975). A
specific antiserum against HL was used in the LPL assay. LPL was inactivated with a substrate
containing 1 M NaCl when measuring the activity of HL. In Study IV, the quantification of LPL
mass was performed by Commercial Markit-F LPL EIA kit (Dainippon pharmaceutical Co,
Ltd., Osaka, Japan) as described in detail elsewhere (Antikainen et al. 1996, Ikeda et al. 1990).
The specific activity of LPL was calculated by dividing LPL activity by LPL mass. 
5.8. Solid-phase minisequencing
A minisequencing method (Syvänen et al. 1993) was used to screen for the point mutation ASG
at position 291 in the 459 bd promoter fragment of the LPL gene. The known point mutation
Asn291Ser in exon 6 of the human LPL gene was amplified by PCR using an upstream PCR
primer 5`-(ATC TTG GTG TCT CTT TTT TAC CC)-3` and biotinylated downstream PCR
primer 5`-(AGT CTT CAG GTA CAT TTT GCT GCT)-3`. The detection primer 5`-(CAA TCT
GGG CTA TGA GAT CA)-3` was used for determining allelic variants with an A at the second
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position of codon 291. The PCR was carried out as described (Mullis and Faloona 1987) in a
total volume of 50 µL. The cycles of denaturation (1 min at 95 bC), annealing (1 min at 54 bC)
and elongation (2 min at 72 bC) were repeated 32 times. For each minisequencing reaction, a
10 µL aliquot of the PCR mixture and 40 µL 20 mM sodium phosphate buffer, pH 7.5,
containing 0.1% Tween 20 were added to microtitre plates (Labsystems, Helsinki, Finland) that
had been coated with streptavidin. The samples were incubated with gentle shaking at 37 bC
for 1.5 hours and washed five times with 350 µL 40 mM Tris-HCl, pH 8.8, 1 mM EDTA, 50
mM NaCl, 0.1% Tween 20, at room temperature. The wells were treated once with 100 µL 50
mM NaOH for 5 min at room temperature and washed five times as above. A reaction mixture
consisting of 0.2 µM detection primer and 0.4 µM ³3HºdATP (37 Ci/ mmol) to detect A at the
second position of codon 291 or 0.4 µM ³3H ºdGTP (37 Ci/mmol) to detect G at this position
was added to each well. The samples were incubated at 50 bC for 10 min and washed as above.
The microtitre plates were treated with 60 µL of 50 mM NaOH for 5 min at room temperature
and the eluted radioactivity was measured in a liquid scintillation counter. 
5.9. Insulin sensitivity in vivo
Whole body insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp
technique as previously described (DeFronzo et al. 1979, Yki-Järvinen et al. 1987). Insulin was
infused in a primed continuos fashion for 2 hours. The rate of the continuous insulin infusion
was 1 mU/kg*min. Normoglycemia was maintained using a 20% glucose infusion. The glucose
infusion rate was adjusted based on plasma glucose measurements, which were performed at
5 minute intervals from arterialized venous blood (DeFronzo, et al. 1979, Yki-Järvinen, et al.
1987). Whole-body insulin sensitivity (M-value) was calculated from the glucose infusion rate
during the second hour of the insulin infusion. The lean body mass and the fat percentage were
measured by bioelectrical impedance analysis (Bio-electrical Impedance Analyzer System, RJL
Systems, Detroit, MI).
5.10. Other analytical methods
Concentrations of TG and cholesterol were measured by automated enzymatic methods using
the Cobas Mira analyser (Hoffman-La Roche, Basel, Switzerland). Retinyl ester concentrations
were analyzed with high performance liquid chromatography as described (Ruotolo et al. 1992).
Concentrations of apoE were measured in plasma and in chylomicron, VLDL1, VLDL2 and
HDL fractions by sandwich ELISA as previously described (Bury et al. 1986) in Studies I and
IV. ApoE phenotyping was performed in serum by isoelectric focusing (Havekes et al. 1987).
In Study III the concentrations of apoA-I and apo A-II were measured by an
immunoturbidimetric method with commercial kits (Boehringer GmbH) and lipoprotein A-I-
particles (LpA-I particles) were quantitated using a differential electroimmunoassay (Sebia,
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Issy-les-Moulineaux, France) (Parra et al. 1990). The concentration of LpA-I:A-II-containing
particles was calculated by subtracting the concentration of LpA-I-particles from
immunoturbidimetrically measured total concentration of apoA-I in serum. ApoCII and apoCIII
concentrations were determined by using single radial immunodiffusion (Daiichi, Pure
Chemical Co., Ltd, Tokyo, Japan). Plasma glucose concentrations were analyzed using the
glucose oxidation method (Beckman Glucose Analyzer, Fullerton, CA) (Kadish et al. 1968).
Concentrations of insulin and C-peptide were measured by radioimmunoassay (Kabi Pharmacia
Diagnostics AB, Uppsala, Sweden and Byk-Sangtec Diagnostica GmbH & Co. KG,
Dietzenbach, Germany, kit No 323 161, respectively). Quality of laboratory measurements was
controlled with commercial samples for cholesterol (CV=2.1%), TG (CV=2.2%), apoA-II (CV
= 3.7%), LpA-I-particles (CV = 8.9%), apoC-II (CV = 1.9%), apoC-III (CV = 3.5%), C-peptide
(CV = 4.1%) and insulin (CV=4.7%). CV for the RE assay ranged from 8.6 to 9.6% for a low
control sample and from 7.1 to 9.9% for a high control sample.
5.11. Statistical methods
All values are expressed as mean ± standard error (SE) of the mean. Logarithmic
transformations were performed for variables with skewed distribution when appropriate.
Within-group changes from baseline to postprandial values were compared by repeated-
measures analyses of variance (ANOVA). Between-group differences of postprandial response
in TRL fractions were calculated in two ways: by repeated measures ANOVA (Studies I - IV)
and by area calculations (each study) (Ludbrook 1994, Matthews et al. 1990). Statistical
comparisons for baseline and area measurements were calculated by using the test of Kruskal-
Wallis and for categorical variables by using the χ2 test. In Study I pairwise comparisons were
calculated with Dunn-Sidàk adjusted Kruskal-Wallis test when significant differences were
found by ANOVA. Pearson´s correlation coefficients were calculated to study associations. In
Study II analyses of covariance were studied using age, BMI, physical activity and alcohol
intake as covariates. In Study V the effects of potential determinants of postprandial apoB-48,
apoB-100 and TG responses in VLDL1 fraction were studied by stepwise multivariate
regression analyses. Data analysis was performed using the SYSTAT statistical package
(SYSTAT Inc., Evanston, IL).
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6. RESULTS
Fasting lipid parameters are presented in Table 4, where control subjects from Studies II and
IV are combined together. Table 5 shows fasting lipid and apolipoprotein concentrations in
TRL fractions and Table 6 presents the apoE phenotypes in the same groups. 
Table 4.Fasting lipoprotein variables in the study groups
Control
Subjects1
Smokers LPL A291S Type 2
diabetics
Total TG 1.11 ± 0.07 1.10 ± 0.08 1.05 ± 0.07 2.52 ± 0.14*
LDL TG 0.19 ± 0.02 0.20 ± 0.01 0.15 ± 0.02 0.20 ± 0.01
HDL TG 0.33 ± 0.02 0.27 ± 0.02* 0.30 ± 0.03 0.37 ± 0.01
Total cholesterol 5.35 ± 0.22 5.22 ± 0.25 4.75 ± 0.28 5.67 ± 0.08
LDL cholesterol 2.87 ± 0.16 2.81 ± 0.21 2.60 ± 0.23 2.96 ± 0.08
HDL cholesterol 1.62 ± 0.08 1.55 ± 0.13 1.31 ± 0.05* 1.17 ± 0.03*
LPL 248 ± 17 218 ± 18 188 ± 15 240 ± 8
HL 282 ± 29 349 ± 22* 340 ± 32 347 ± 20
1 Combined from studies II and IV. Data are mean ± SE.
Lipid concentrations are in mmol/l. Postheparin lipoprotein lipase (LPL) and hepatic lipase (HL)
activities are in mU/ml.
*p < 0.05 compared with control subjects
6.1. Comparison of postprandial responses after three different fat loads (Study I)
Fasting lipids and lipoproteins Fasting plasma TG concentrations were 1.10 ± 0.08 mmol/L
before the mixed meal, 1.00 ± 0.09 mmol/L before the soybean-oil meal and 1.01 ± 0.10
mmol/L before the cream meal, respectively. The fasting concentrations of TG, cholesterol,
apoB-48, apoB-100 and apoE were similar in each TRL fraction. LDL and HDL cholesterol
concentrations were also comparable before the fat loads.
Postprandial TG, apoB-48 and apoB-100 The postprandial responses of TG, apoB-48 and
apoB-100 were similar after the fat loads (Figure 3). The maximum concentrations of TG were
reached at three hours after the fat loads. The slope of apoB-48 curves closely paralleled those
of TG responses in the chylomicron, VLDL1 and VLDL2 fractions. The concentration of TG,
apoB-48 and apoB-100 returned to the baseline at six to eight hours after the meals. The
postprandial response of plasma TG correlated closely with fasting plasma TG and inversely
with HDL cholesterol concentrations (r > 0.863, p < 0.001 and r < -0.694, p < 0.036 after each
fat load, respectively). 
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Table 5. Fasting lipid and apolipoprotein concentrations in triglyceride-rich lipoprotein fractions
Control
Subjects1
Smokers LPL A291S Type 2
diabetics
Sf  > 400 Chol 0.007 ± 0.0 0.002 ± 0.0 0.004 ± 0.0 0.03 ± 0.01
TG 0.04 ± 0.02 0.02 ± 0.01 0.03 ± 0.01 0.15 ± 0.02*
ApoB-100 0.03 ± 0.01 0.10 ±0.06 0.09 ± 0.04* 0.61 ± 0.11*
ApoB-48 0.007 ± 0.0 0.006 ± 0.0 0.002 ± 0.0 0.06 ± 0.02*
Sf 60 - 400 Chol 0.08 ± 0.01 0.12 ± 0.02* 0.15 ± 0.03* 0.40 ± 0.03*
TG 0.29 ± 0.04 0.39 ± 0.05* 0.51 ± 0.11* 1.15 ± 0.02*
ApoB-100 17.6 ± 3.4 28.8 ± 6.1 44.2 ± 9.1* 56.5 ± 4.8*
ApoB-48 0.54 ± 0.12 0.86 ± 0.18 0.49 ± 0.12 1.69 ± 0.03*
Sf 20 - 60 Chol 0.15 ± 0.02 0.12 ± 0.02 0.15 ± 0.02 0.33 ± 0.02*
TG 0.19 ±0.03 0.14 ± 0.02 0.18 ± 0.02 0.36 ± 0.03*
ApoB-100 35.3 ± 5.4 25.7 ± 3.6 41.9 ± 4.6 60.5 ± 5.2*
ApoB-48 0.48 ± 0.16 0.60 ± 0.10 0.43 ± 0.12 1.22 ± 0.22*
Sf 12 - 20 Chol 0.23 ±0.03 0.16 ± 0.03 0.19 ± 0.02 0.34 ± 0.02*
TG 0.08 ± 0.01 0.05 ± 0.01* 0.06 ± 0.01* 0.10 ± 0.01
ApoB-100 164 ± 26 111 ± 18 140 ± 21 201 ± 19
ApoB-48 0.59 ± 0.09 0.56 ± 0.07 0.36 ± 0.10 0.75 ± 0.11
1 Combined from studies II and IV
Lipid concentrations are in mmol/l and apolipoprotein B-48 and B-100 concentrations are in mg/l.
Data are mean ± SE.
*p < 0.05 compared with control subjects
Table 6. Apolipoprotein E phenotypes in the study groups
ApoE phenotype Control
Subjects1
Smokers LPL A291S Type 2
diabetics
36221 15 9 6 17
36222 7 3 4 12
36194 - - - 2
36253 - - - 2
1 Combined from studies II and IV
Values are number of subjects in each group.
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Postprandial retinyl esters After the soybean-oil meal, the upstroke of the retinyl ester
concentration curve was faster in the plasma, chylomicron and VLDL1 fractions than after
saturated fat (mixed meal or cream). Consequently, the concentrations of retinyl esters in
plasma were different at 3 hours, being higher after the soybean oil fat load compared with the
mixed meal (p = 0.021) and compared with the cream meal (p = 0.015). The difference was still
significant at 4 hours after ingestion of soybean oil compared with the mixed meal (p = 0.028)
and compared with cream (p = 0.082). The changes in plasma retinyl ester concentrations were
due to alterations in chylomicron and VLDL1 fractions. 
After each meal, the return of the retinyl ester concentrations to the fasting levels was retarded
in comparison with the decline in apoB-48 concentration after the respective meals.
Postprandial retinyl ester AUCs for TRL fractions are shown in Figure 3. Retinyl ester area
under incremental curve (AUIC) in chylomicrons was increased after soybean-oil (p = 0.002
Figure 3. 
Postprandial responses (area under curve,
AUC) of triglycerides (TG), retinyl esters, and
apolipoprotein (apo) B-48 after mixed meal,
soybean oil meal, and cream meal. Sf > 400
(chylomicron), Sf 60-400 (VLDL1), and Sf
20-60 (VLDL2) fractions. P < 0.05 for retinyl
ester AUC after soybean oil compared to
mixed meal and cream meal (Dunn-Sidák
adjusted Kruskal-Wallis test).
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compared with mixed meal and p = 0.022 compared with cream meal). On the contrary, in
VLDL2 fraction both AUCs and AUICs were comparable between the meals. Fasting
concentrations of TG and postprandial plasma retinyl ester responses were correlated after each
fat load (r > 0.577, p < 0.081). This implies that although the retinyl ester responses after the
soybean meal peaked earlier than after saturated fat, the subjects with higher fasting TG
concentrations displayed larger retinyl ester responses than subjects with lower fasting TG
concentration.
Postprandial apoE Postprandially apoE levels increased significantly compared with fasting
levels in chylomicron (p < 0.016 after each meal), in VLDL1 (p < 0.013) and in VLDL2 (p <
0.077) fractions. This increase in apoE concentration was similar among the three fat loads.
HDL apoE concentration tended to decrease from fasting levels after fat ingestion,
concomitantly with TRL apoE increase.
Postprandial cholesterol The concentration of cholesterol increased significantly from fasting
levels after each meal in plasma, chylomicron, VLDL1 and VLDL2 fractions but it remained
unchanged in IDL, LDL and HDL fractions. No differences existed in postprandial HDL
cholesterol concentrations at baseline and the responses after each meal were comparable. In
the chylomicron fraction, the postprandial cholesterol concentration after soybean oil was
significantly higher than after the other meals (p < 0.044). In other lipoprotein fractions the
cholesterol responses were comparable after the different meals.
6.2. Postprandial lipid metabolism in smokers (Studies II and III)
Fasting metabolic parameters Each subject had normal fasting glucose levels. Postprandially
no significant differences between smokers and control subjects were observed in
concentrations of glucose, insulin, or C-peptide. Fasting lipid parameters are listed in Table 4.
The smokers and the control subjects were selected to have comparable fasting TG and HDL
cholesterol concentrations. Furthermore, when the control subjects from Studies II and IV are
combined together, these parameters are very similar. Fasting plasma unesterified cholesterol
concentration tended to be lower in smokers than in controls (1.54 ± 0.07 vs. 1.67 ± 0.08, p =
n.s.), which is in line with fasting total cholesterol concentrations (Table 4). Compared with
control subjects, smokers had higher HL activity. 
Postprandial lipemia in total plasma Despite similar fasting concentrations of plasma TG, the
postprandial concentration curve of plasma TG was higher in smokers than in control subjects
(p = 0.012). The peak concentrations occurred at 4 hours in smokers (2.56 ± 0.45 mmol/L) and
at 3 hours in control subjects (1.50 ± 0.12 mmol/L). In whole plasma, the smokers showed a
significant decrease in postprandial cholesterol concentration (p = 0.038), whereas the
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concentration remained unchanged compared with fasting values in control subjects. Plasma
unesterified cholesterol clearly increased postprandially from fasting levels in smokers (p =
0.001), but not in control subjects. 
Figure 4. 
Postprandial responses in Sf 60-400 (VLDL1)
fraction in smokers («) and in control subjects
(¬). ANOVA, repeated measures analysis of
variance; apo, apolipoprotein; RE, retinyl esters;
TG, triglycerides.
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Postprandial lipemia in Sf > 400 fraction In the chylomicron fraction, smokers displayed
higher TG, apoB-48, retinyl ester and apoE responses to the mixed meal than the control
subjects. Adjustment for potential confounders (age, BMI, physical activity and alcohol intake)
did not change the significance of any parameter. The peak concentrations of TG, apoB-48,
apoE and cholesterol in this fraction were delayed until 4 to 6 hours after the meal in smokers
compared with earlier peaks observed in control subjects. The peak of the retinyl ester
concentration occurred at 6 hours after the fat load in both groups. The concentrations of apoB-
100 and cholesterol were higher at each time-point in smokers but the differences were not
statistically significant.
 
Postprandial lipemia in Sf 60 - 400 fraction The concentration curves for TG, retinyl esters,
apoB-48, apoB-100 and apoE in VLDL1 fraction are presented in Figure 4. As expected, the
AUC and AUIC values of these parameters were higher in smokers than in control subjects.
Adjustment for potential confounders (age, BMI, physical activity and alcohol intake) did not
influence the significance of any parameter. Postprandial apoB-100 concentrations were
comparable between the two groups.
Postprandial lipemia in Sf 20-60 and Sf 12-20 fractions In smokers, VLDL2 TG and apoB-48
concentrations increased postprandially from fasting levels. In controls, no changes were
observed compared with fasting values in this fraction. Thus, the difference between the two
groups was significant. Retinyl ester and apoB-100 responses were similar between smokers
and control subjects. Interestingly, higher TG and apoB-100 responses in the IDL fraction were
noted in control subjects when compared with smokers. Postprandial IDL cholesterol tended
to be lower in smokers as well.
Postprandial changes in HDL lipids and lipoproteins The reduction of plasma cholesterol was
due to the decrease of postprandial HDL cholesterol concentration from fasting values in
smokers (p < 0.001). The response of HDL cholesterol concentrations to the fat load was
different between smokers and controls (p = 0.006). Despite similar fasting concentrations, the
HDL cholesterol concentration at 4 hours was 8.5% lower in smokers as compared with
controls (1.42 ± 0.11 mmol/L in smokers vs. 1.62 ± 0.12 mmol/L in controls). In smokers,
plasma apoE concentrations fell postprandially due to a marked decrease of apoE in the HDL-
fraction when compared with fasting levels (p < 0.001). In contrast, HDL apoE concentration
remained unchanged in control subjects (p = 0.726). In smokers, plasma apoA-I and LpA-I
concentrations decreased significantly postprandially from baseline levels (p = 0.032 and p =
0.002, respectively), but remained unchanged in controls. The changes in apoA-I and LpA-I
concentrations correlated with concomitant changes in HDL cholesterol in both groups (for
smokers r > 0.603 and p < 0.035 for each value, and for controls r > 0.703 and p < 0.011 for
each value). LpA-I:AII particle concentrations remained postprandially unchanged in both
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groups.
Lipid transfer protein activities and esterification rates Fasting esterification rates and activities
of CETP, LCAT and PLTP and the respective maximal changes after the fat load are shown in
Table 7. Although fasting esterification rates were similar, significant reduction in postprandial
esterification rate was observed in smokers when compared with control subjects (p = 0.026).
Both baseline and postprandial plasma LCAT activity levels were comparable in the two groups
and LCAT levels were virtually identical between smokers and control subjects. The
phospholipid transfer rate, measured with endogenous HDL and plasma PLTP activity level,
measured with excess of exogenous HDL (% of reference plasma), decreased after the fat load
in smokers compared with their baseline values (p < 0.001 and p = 0.017, respectively) but not
in the control subjects. Consequently, the phospholipid transfer rate (% transfer) was
significantly lower postprandially in smokers than in control subjects (p = 0.007). Plasma CETP
activity levels were unchanged postprandially in controls but decreased slightly in smokers after
the fat load. The CETP activity was significantly lower in smokers (p = 0.006) than in controls
through the study period. The activity of CETP correlated with plasma cholesterol
concentration in both groups (r > 0.586, p < 0.055 in smokers and r > 0.711, p < 0.012 in
controls at each time point). 
Correlation studies In control subjects, we observed an inverse correlation between plasma TG
AUC and postheparin LPL activity r = -0.609, p = 0.047). In contrast, these two parameters did
not correlate in smokers (r = 0.034). Postheparin LPL activity and free fatty acid AUC
correlated among the control subjects (r = 0.641, p = 0.033) but not in the smokers (r = 0.281).
Triglyceride AUIC correlated positively with apoE AUIC in chylomicrons and VLDL1 in both
groups. In contrast, TG AUIC correlated negatively with apoE incremental area in HDL fraction
in smokers (r = -0.613, p = 0.034) but not in controls (r = -0.067). 
Table 7. Fasting and postprandial (6 hours) lipid transfer protein activities in smokers and control
subjects
Smokers Controls
fasting pp change fasting pp change
LCAT (% ref plasma) 99 ± 3 ¡ 6 % 101 ± 5 ¡ 5 %
PLTP (% transfer) 9.0 ± 0.4 ¢ 13 % 9.1 ± 0.4 ¢ 3 %
CETP (% ref plasma) 76 ± 6 ¢ 6 % 94 ± 8 ¡ 2 %
Esterif. rate (nmol/ml/h) 102 ± 6 ¡ 34 % 99 ± 7 ¡ 12 %
Data are mean ± SE and maximal postprandial (pp) change in percentages.
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6.3. Influence of LPL Asn291Ser gene polymorphism on insulin sensitivity and
postprandial lipid metabolism (Study IV) 
Fasting lipids Carriers with normal concentrations of plasma TG (< 1.7 mmol/L) were eligible
for the study. The range of fasting TG was from 0.79 to 1.43 mmol/L in carriers and from 0.70
to 1.53 mmol/L in control subjects. As compared with the normolipidemic control subjects, the
carriers had similar fasting concentrations of TG, total cholesterol and LDL cholesterol but
lower fasting HDL cholesterol concentrations. Although VLDL TG concentrations tended to
be higher in carriers, the differences were not significant. The two groups displayed comparable
concentrations of fasting apoB-48 in chylomicron, VLDL1 and VLDL2 fractions. However,
fasting concentrations of apoB-100 in chylomicron (p = 0.022) and VLDL1 (p = 0.01) fractions
were higher in carriers than in control subjects. Fasting free fatty acid concentrations were
similar in the carriers (747 ± 118 mmol/L) and in the control subjects (658 ± 71 mmol/L).
Lipase activities The postheparin LPL activity was 19% lower in carriers compared with control
subjects (p = 0.082). The mass and specific activity of LPL were measured in 8 carriers and in
8 control subjects. LPL mass did not differ significantly between the groups (188 ± 15 ng/ mL
in carriers and 226 ± 18 ng/ mL in control subjects). By contrast, the specific activity of LPL
in carriers of Asn291Ser variant was 11% lower than in control subjects, p = 0.016. Postheparin
HL activity was 40% higher in carriers than in control subjects (p = 0.054). Compared with
controls, carriers had significantly lower LPL to HL ratio (p = 0.010). 
Insulin sensitivity Fasting glucose concentrations and glucose utilization rate during insulin
infusion are presented in Figure 5. Fasting serum insulin concentrations were comparable
between the groups.
Figure 5. 
Glucose utilization rate during insulin infusion and fasting plasma glucose concentrations in
carriers of Asn291Ser variant in LPL gene (A291S) and in control subjects.
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Figure 6. 
Postprandial responses in Sf 60-400 (VLDL1)
fraction in carriers of Asn291Ser variant in LPI, gene
(«) and in control subjects (¬). Bar graphs illustrate
the area under curve (AUC) responses. ANOVA,
repeated measures analysis of variance; apo,
apolipoprotein; C, control subjects; RE, retinyl
esters; TG, triglycerides; 291+, carriers of
Asn291Ser variant in LPL gene.
Postprandial lipemia in plasma and TRL fractions In total plasma the carriers had a higher
AUC response for TG (p = 0.038) but a similar AUC response for retinyl esters compared with
controls. Concentrations of apoB-48 and thus the metabolism of exogenous particles in the
chylomicron fraction appeared very similar in the two groups in both the fasting and
postprandial states. The postprandial concentrations curves of TG, retinyl esters, apoB-48,
apoB-100 and apoE and the respective AUCs are shown in Figure 6. The differences in VLDL1
TG, cholesterol and apoB-100 concentrations were most marked at the late postprandial hours.
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Postprandial retinyl ester concentrations in chylomicron, VLDL1 and VLDL2 fractions at 9 and
12 hours were significantly higher in the carriers than in the control subjects. Together these
changes suggested delayed clearance of both intestinal and hepatic large TRL particles in the
carriers. Concentrations of TG, cholesterol, apoB-48 and apoB-100 were comparable in VLDL2
and IDL fractions.
Figure 7. 
Postprandial concentrations of cholesterol (chol),
triglyceride (M) and cholesterol to TG-ratio in HDL
fraction. Carriers of Asn291Ser variant in LPL gene
(«) and in control subjects (¬). ANOVA, repeated
measures analysis of variance.
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High density lipoprotein subfraction HDL cholesterol concentration decreased during
alimentary lipemia compared with fasting values in the two groups (p < 0.001 for both). In the
control group the lowest HDL cholesterol concentration occurred at 3 hours after the fat intake.
In the carriers the lowest HDL cholesterol level was observed at 6 hours after the meal. In the
HDL fraction the TG concentration increased postprandially in carriers compared with the
fasting value (p = 0.048). In contrast, HDL triglycerides tended to decrease after the fat load in
control subjects (p = 0.063). Consequently, carriers and control subjects had clearly different
HDL cholesterol and TG curves postprandially (Figure 7). Respectively, the calculated
TG/cholesterol-ratio in HDL fraction differed between the groups. In the fasting state the ratio
was similar (carriers 0.22 ± 0.02 and control subjects 0.23 ± 0.03). Postprandially, this ratio
increased in carriers as a sign of TG enrichment in the HDL fraction. In control subjects, the
TG/cholesterol-ratio remained practically unchanged during fat load.
Correlation studies In the control group, as expected, LPL activity correlated inversely with the
AUC response of apoB-48 in the VLDL1 fraction (r = - 0.672, p = 0.033). Notably, this
correlation was not found in carriers (r = 0.486).
6.4. Relationship between the severity of coronary artery disease and postprandial
apolipoprotein B-48 and B-100 responses in type 2 diabetes (Study V)
Fasting lipids and lipoproteins The fasting lipids and lipase activities were comparable between
subjects with mild and severe CAD as indicated in Table 3. Postprandial data from ten healthy
males from Study I are presented in the original article for comparison. As evident from Table
4, the type 2 diabetic subjects exhibited the classic dyslipidemia of diabetes with low HDL
cholesterol and high TG concentration. Notably, LDL cholesterol concentration was normal in
type 2 diabetic subjects. In comparison to control subjects the type 2 diabetic subjects displayed
the most pronounced differences in VLDL1 and VLDL2 fractions, in which TG, cholesterol,
apoB-48 and apoB-100 concentrations were elevated (Table 5). In the chylomicron fraction, the
concentration of fasting apoB-48 was 9 times higher and that of apoB-100 was 20 times higher
in diabetic subjects than in control subjects. In diabetic subjects, comparable LPL activity but
significantly increased HL activity in postheparin plasma was observed when compared with
healthy subjects.
Postprandial lipemia in total plasma Postprandial TG concentration in whole plasma was
similar between the groups with mild and severe CAD. The peak of TG concentration was
reached at 3 hrs and the return to the fasting level was equally slow in both groups. The plasma
TG concentration, 8 hours after the fat load was still markedly elevated with values of 3.68 ±
0.34 mmol/L (mild CAD) and 4.33 ± 0.36 mmol/L (severe CAD) (p < 0.001 compared with
fasting plasma TG concentration in both groups). The postprandial AUC and AUIC values for
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TG in plasma did not differ statistically between the two groups (data not shown). The
responses of retinyl esters in plasma were parallel to those of plasma TG. Both TG and retinyl
ester responses were significantly higher in type 2 diabetics compared with non-diabetic
subjects.
 
Postprandial lipemia in TRL fractions The groups with mild and severe CAD had comparable
TG, apoB-48 and apoB-100 responses in chylomicron, VLDL1, VLDL2 and IDL fractions and,
accordingly, the calculated AUC and AUIC responses did not differ statistically between the
groups. The concentrations of these parameters were clearly increased in chylomicron and
VLDL1 fractions but instead, the respective concentrations in VLDL2 and IDL fractions did
not change after the fat load in either group. The peak of TG, apoB-48 and apoB-100
concentrations were reached at 3 hrs in chylomicron and VLDL1 fractions. In neither group did
these parameters reach fasting concentrations at the end of the fat load test. In the IDL fraction,
the apoB-100 concentration tended to be higher in the subjects with severe CAD. In both
groups, the apoB-100 concentration in the IDL fraction decreased significantly during
alimentary lipemia. The responses of TG, apoB-48 and apoB-100 in all TRL fractions were
markedly higher in both groups, comparing diabetic with non-diabetic subjects.
Postprandial responses of HDL fraction The cholesterol concentration in the HDL fraction
decreased after the fat load in the mild and severe CAD groups (p < 0.001 for both). The lowest
concentration of HDL cholesterol occurred 6 hours after the fat load in both groups. In HDL
fractions the TG/cholesterol-ratio increased postprandially (p < 0.019 for both groups). Both
fasting and postprandial HDL cholesterol concentrations in diabetic subjects were substantially
lower than in non-diabetic subjects.
Multivariate analysis Multivariate analyses were performed to adjust for baseline
characteristics (sex, duration of diabetes, waist-hip ratio, diastolic blood pressure, fasting
glucose, glycosylated HbA1C, use of insulin and use of β-blockers). Adjusted p-values were
essentially similar to crude p-values, i.e. no differences in measurements of postprandial
lipemia were found between the groups with mild and severe CAD.
Correlations between the severity of CAD and postprandial lipemia The correlation between
lipid and lipoprotein parameters and the severity of CAD as indicated by coronary angiogram
was calculated for the 16 subjects with mild CAD and the 9 evaluable subjects with severe
CAD who had not undergone a revascularization procedure. The severity of the tightest
coronary stenosis correlated with postprandial responses (AUC) for plasma TG (r = 0.492, p
= 0.013) and chylomicron TG (r = 0.443, p = 0.026). We also observed a correlation between
maximal stenosis and AUC for chylomicron apoB-48 (r = 0.461, p = 0.041). The strongest
correlate of maximal stenosis was AUIC for apoB-100 in the IDL fraction. Because the AUIC
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measurement represents the change in postprandial IDL particle numbers, we calculated
correlations for maximal stenosis and ∆IDL apoB-100 concentrations at 4 hours (r = 0.504, p
= 0.024), 6 hours (r = 0.413, p = 0.070) and 8 hours (r = 0.572, p = 0.008) after the fat load.
Apolipoprotein E phenotype and postprandial lipemia In type 2 diabetic subjects the proportion
of mild or severe CAD (p = 0.817) was not different in subjects with apoE3/3 phenotype (n =
27) compared with subjects with either 3/4 or 4/4 phenotype (n = 14) Postprandial responses
of TG, apoB-48 and apoB-100 were compared between the two groups and each of the AUC
and AUIC responses were found closely comparable. Figure 8 displays apoB-48 and apoB-100
responses in VLDL1 fraction as an example.
Figure 8. 
Postprandial responses of apolipoprotein (apo) B-48 and B-100 in Sf 60-400 MD1,1) fraction in type 2
diabetic subjects divided according to apoE phenotype. Subjects with apoE 3/3 phenotype («) and subjects
with apoE3/4 or E4/4 (¬). P = n.s. by repeated measures analysis of variance.
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7. DISCUSSION
7.1. Evaluation of the study methods and design 
In the present study we separated intestinal TRL particles by using two methods. Firstly, the
gut-derived particles were labeled by oral vitamin A administration and concentrations of
retinyl esters were determined in TRL fractions separated by ultracentrifugation. Secondly, the
concentrations of apoB-48 were quantified in the corresponding fractions. The use of retinyl
esters as a marker for apoB-48 particles has been widely studied. Administration of vitamin A
has commonly been used to trace chylomicrons and chylomicron remnants. Retinyl esters are
transported in chylomicrons and their remnants to the liver and are not considered to be
exchanged between lipoprotein species or to be re-secreted in VLDL particles (Lenich and Ross
1987, Thompson et al. 1983). However, we in accordance with others (Berr and Kern 1984,
Demacker et al. 1992, Krasinski, et al. 1990a, Wilson et al. 1983) have detected increasing
concentrations of retinyl esters in LDL and HDL fractions in the late postprandial hours.
Furthermore, in the present study the retinyl ester response, especially in VLDL2 fraction, did
not parallel that of apoB-48. Beyond this, the retinyl ester concentrations in the VLDL2 fraction
increased until 8 to 9 hours postprandially in healthy control subjects, whereas VLDL2 apoB-48
concentrations were practically similar to fasting concentrations during the late postprandial
hours. Measurement of apoB-48 by SDS-PAGE enables simultaneous measurement of the
hepatic input, i.e. the apoB-100 concentration, to the postprandial lipemia. Methodological
problems in apoB-48 determinations arise from its low concentration and structural similarity
to apoB-100. In this study the detection limit and CV for the two subspecies of apoB were
comparable with those of previous reports (Karpe and Hamsten 1994, Schneeman, et al. 1993).
Another disadvantage is that measurement of retinyl esters does not allow the study of
metabolism of hepatic VLDL and VLDL remnants, which contribute significantly to
postprandial lipemia (Cohn, et al. 1989, Schneeman, et al. 1993) and most likely, to the
development of atherosclerosis.
Measurements of both apoB-48 and retinyl ester concentrations require separation of TRLs into
lipoprotein fractions by ultracentrifugation. Ultracentrifugation may potentially induce
compositional changes in lipoproteins due to high salt concentration and gravitational forces.
Another limitation is that these methods do not give direct information as to whether the
postprandial changes of apolipoprotein or retinyl ester concentrations are due to increased
synthesis or decreased catabolism of TRL particles. Furthermore, measurement of retinyl esters,
apoB-48 and apoB-100 in the postprandial state is based on the assumption that TRL particles
stay in the intravascular space until removed by tissue receptors. However, a proportion of the
particles may reside in another compartment, i.e. be marginated (Hultin, et al. 1996, Karpe, et
al. 1997b). If a significant proportion of TRL particles are marginated in the postprandial state,
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the measured plasma concentrations of parameters used in these studies may be underestimated.
The present studies investigate the metabolism of TRLs and HDL after ingestion of a fat meal
in healthy subjects, smokers, carriers of LPL Asn291Ser gene variant and type 2 diabetic
subjects. The limitations in these studies arise from the tedious methodology, and thus the
groups are small in numbers of subjects. Selection bias must be considered as well, since the
groups do not arise from random population samples. Other potential confounding factors
include age, body composition and physical fitness, which may modify lipid metabolism.
7.2. The effect of fat composition on the postprandial lipid response (Study I)
To avoid the effect of variable fasting TG on postprandial lipemia (Cohn, et al. 1988b), the
subjects were instructed to keep their lifestyle constant during the three fat loads. Despite the
differences in fatty-acid composition and in carbohydrate and energy content of the fat loads,
the postprandial responses of TG, apoE, apoB-48, apoB-100 and HDL-cholesterol were
comparable when the amount of fat was identical. The uniformity of the postprandial apoB-48
concentrations indicates that after different fat loads, the number of intestinally formed
chylomicron particles was similar independent of the type of fat used. Peak concentrations of
TG, apoE and apoB-48 occurred mainly 3 hours after the meals in the chylomicron and VLDL1
fractions. Likewise, the peak responses of apoB-100 in these fractions were observed at 3-4
hours after fat intake. This, together with the prompt decline in the concentrations of TG, apoB-
48 and apoB-100 in the fractions containing large TRL particles, implies rather similar lipolytic
rate and hepatic clearance of TRL particles of both intestinal and hepatic origin, despite the
different fat loads. On the other hand, increasing amounts of sunflower oil (from 0 to 50 g)
given to eight healthy males introduced stepwise increases in the serum and chylomicron TG
response. Differences in postprandial response were detected even with a 10 g change in the
amount of fat (Dubois et al. 1998). Thus, the total quantity of fat appears more important than
the quality of fat as a determinant of the postprandial TG, apoB-48, apoB-100 and apoE
responses.
Despite similar responses of TG, apoB-48, apoB-100 and apoE, the response of retinyl esters
differed significantly when saturated fat (cream or mixed meal) was used as a fat source as
compared with polyunsaturated fat (soybean-oil). After soybean-oil, the retinyl ester response
in chylomicron and VLDL1 fractions was significantly increased compared with the two other
fat loads. However, the peak concentrations of retinyl esters paralleled those of TG and apoB-
48 in these fractions. Other studies using soybean oil have reported conflicting results. In line
with our data, Cohn et al. (1988a) have shown a concomitant appearance of peak concentrations
of retinyl palmitate and apoB-48 after soybean oil. In contrast, in other studies (Karpe, et al.
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1995, Krasinski, et al. 1990a, Lemieux et al. 1998), postprandial retinyl palmitate peak was
delayed compared with apoB-48 peak. These variations in results may partly be accounted for
by differences in the separation of Sf 12-60 fractions. 
In accordance with our findings, previous study by Cohn et al. (1993) reported delayed retinyl
palmitate peak with plasma TG and TRL apoB-48 after a cream meal. After saturated fat, the
retinyl ester response in chylomicron and VLDL1 fraction was markedly delayed, occurring 6-8
hours after fat ingestion. In VLDL2 and IDL fractions the retinyl ester concentrations increased
throughout the study period. These observations contrasted responses of TG and apoB-48 in
the respective fractions, which declined to fasting values at 6-8 hours after the fat loads. This
finding is concordant with previous observations in healthy subjects. Hepatic uptake of TRL
remnants was found saturable after an oral fat load in a study by Berr (1992), in which the
chylomicron remnant concentration exceeded the putative saturation concentration for 7 hours
after ingestion of 70 g of fat.
 
Karpe et al. found a varying number of retinyl palmitate molecules per particle in TRL fractions
and suggested direct secretion of smaller chylomicron particles from the intestine (Karpe, et al.
1995). We observed higher cholesterol concentration and slightly elevated TG AUIC in the
chylomicron fraction after soybean oil, which, together with the unchanged concentration of
chylomicron apoB-48, may indicate secretion of larger exogenous chylomicrons after
polyunsaturated fat. These larger particles and their remnants may contain different amounts
of retinyl esters per TRL particle than the intestinal particles formed after a mixed meal or
cream. The concept is supported by the larger chylomicron AUC for retinyl esters after a
soybean oil meal.
Hypothetically, one explanation for differences in retinyl ester concentrations of large TRL
particles may be, as suggested by a recent study (Karpe et al. 1997a), that the largest
chylomicron remnants are removed by VLDL receptor in the periphery to some extent. The type
of fat could also influence this mechanism. Another possibility is, as demonstrated previously
(Blaner et al. 1994, Hultin, et al. 1996, Van Bennekum et al. 1999), direct hydrolysis of retinyl
esters by LPL. The experiments of Hultin et al. suggested that with a large excess of LPL, up
to one third of retinyl esters were hydrolyzed. However, such excess of LPL is not found after
fat intake under physiological conditions and therefore, the hydrolysis of retinyl esters from
TRL particles is an unlikely explanation for the observed differences.
Interestingly, the postprandial response of retinyl palmitate but not of TG or apoB-48/apoB-100
ratio has been found to be dependent on the apoE-phenotype in a study of more than 470
subjects (Boerwinkle, et al. 1994). The E2-allele was associated with a higher retinyl palmitate
response to a fat load than other alleles and accounted for 7.1% of the interindividual variation
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in retinyl palmitate response 8 hours after oral fat load. This observation provides further
evidence for different metabolism of vitamin A compared with apoB-48. 
We observed no differences in apoE response in plasma, TRL and HDL fractions to the three
different fat loads. Thus, the soybean oil-derived large chylomicrons seem to be similar
acceptors of HDL-derived apoE to the chylomicrons after a mixed meal or cream. This and the
similar decline in chylomicron apoB-48 concentration suggest that the removal of intestinal
TRL remnants by hepatic receptors is not affected by the different fat loads used in this study.
7.3. The effect of smoking on postprandial apolipoprotein B-48 and B-100 metabolism,
lipid transfer activities and high density lipoprotein metabolism (Studies II and III)
To the best of our knowledge, this is the first study to describe in detail the effect of smoking
on TRL metabolism. In smokers, dyslipidemia with high TG / low HDL concentrations (Craig,
et al. 1989) and preliminary findings of excessive postprandial TG response (Axelsen, et al.
1995, Elkeles, et al. 1983) led us to expect that fat intolerance is an inherent feature of lipid
abnormalities, and furthermore, may contribute to the risk of CAD caused by cigarette smoking.
Consequently, we decided to define the abnormalities of postprandial lipid metabolism in
smokers compared with non-smoking control subjects. Since fasting TG is a determinant of
postprandial lipemia (Cohn, et al. 1988b), we recruited smokers with fasting TG < 1.7 mmol/L.
The concentration of fasting TG averaged 1.10 ± 0.08 mmol/L in smokers and 1.11 ± 0.07
mmol/L in control subjects. The major result was that normolipidemic smokers have an
enhanced postprandial response due to abnormal metabolism of apoB-48 particles. Two
independent markers of intestinal TRL particles, RE and apoB-48, were closely correlated with
the high TG response in smokers. Thus, the data indicate accumulation of large chylomicron
remnants in Sf > 60 fractions as the main feature of fat intolerance in smokers. In addition,
apoB-100 concentrations in chylomicron and VLDL1 fractions were higher throughout the
study in smokers, though the difference was not statistically significant.
Previous investigations suggesting an adverse effect of smoking on postprandial lipid
metabolism includes three human studies and two animal studies. The studies in healthy males
have investigated the effect of smoking on postprandial total plasma TG and HDL
concentrations. Elkeles et al. (1983) studied lean medical students after an oral fat load. The
regular smokers smoked a cigarette per hour during the test. Plasma TG concentration was
higher throughout the study and there was a lack of increase in HDL2/HDL3 cholesterol ratio
in smokers compared with control subjects. Axelsen et al. (1995) were the first to report high
postprandial plasma TG response in smokers. Our study (Eliasson, et al. 1997) confirmed this
finding and linked the fat intolerance in smokers to high proportions of small dense LDL
particles. In these studies fasting TG levels tended to be higher and HDL cholesterol
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concentrations lower in smokers than in the control group. In the animal studies, rats exposed
to cigarette smoke for ten days showed delayed hepatic clearance of 14C-labeled chylomicron
cholesterol. In the second set of experiments, smoke-treated chylomicrons injected to rats not
exposed to smoke displayed prolonged residence-time in tissues (heart) and delayed hepatic
clearance (Pan et al. 1993). A recent study by the same group investigated the acute and
subacute effects of cigarette smoke on clearance of chylomicrons and chylomicron remnants
and activities of LPL and HL in rats after a fat-containing meal. The clearance of chylomicron
TG and cholesterol was delayed by smoke exposure but this could not be explained by changes
in either LPL or HL activities (Pan et al. 1997). Together, these studies show close agreement
with our findings of delayed clearance of apoB-48 remnant particles.
Why is the clearance of chylomicrons and their remnants delayed in smokers? The data of Pan
et al. (1993, 1997) implied that there is a direct effect of cigarette smoke on chylomicron
remnant clearance. A review by Freeman and Packard (1995) suggested that TG metabolism
in adipose tissue is abnormal in smokers. Smokers have increased activity of hormone sensitive
lipase (HSL) most likely due to nicotine-induced chronic cathecholamine stimulation (Brunzell,
et al. 1980, Creyer, et al. 1976) and furthermore, insulin fails to suppress the activity of HSL
(Chajek-Shaul, et al. 1990), which may lead to higher FFA supply to liver and stimulation of
VLDL synthesis. Our observation that postprandial FFA responses tended to be higher in
smokers supports the concept of enhanced lipolysis.
Recently, smokers were shown to have reduced LPL activity in postheparin plasma (Freeman
et al. 1998). Smokers in this study showed a tendency for subnormal LPL activity (18% lower
compared with control subjects). Reduced LPL activity may contribute to the delay of TRL
remnant clearance. A lack of correlation between LPL activity and postprandial TG response
observed in smokers may also indicate abnormal interaction of LPL with TRL particles. This
would also be consistent with previous findings that smokers are insulin resistant (Eliasson, et
al. 1994, Facchini, et al. 1992), a condition associated with subnormal LPL activity. We did not
directly measure insulin sensitivity but smokers in our study displayed similar glucose and C-
peptide concentrations and were devoid of features of the insulin resistance syndrome other
than enhanced postprandial lipemia. However, the data from rats contradicts this hypothesis by
showing that exposure to cigarette smoke does affect the hydrolysis of chylomicrons by
endothelial LPL (Pan, et al. 1997). Furthermore, the LPL function is rarely critical for
chylomicron clearance but theoretically the interaction between TRL particle and LPL-heparan
sulfate complexes may be impaired by smoking. 
Interestingly, smokers seem to have increased activity of HL (Moriguchi et al. 1990). This
observation was also supported by the current data when the two control groups were compared
with smokers (Table 4). HL does not hydrolyze TRL particles but is involved in the clearing
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process of TRL remnants by augmenting binding to hepatic receptors (Ji, et al. 1994b).
Therefore, high HL activity is not likely to augment postprandial lipemia, but rather assure the
clearance of TRL by the liver. However, increased HL activity may contribute to the reduction
of HDL cholesterol in smokers as previously suggested (Moriguchi, et al. 1990) and noted
postprandially in the present study. Enhanced postprandial catabolism of HDL is supported by
the decrease of HDL cholesterol concentration and by declines in apoA-I and HDL apoE
concentrations in smokers.
HDL is the main source of apoE, which is transferred to the TRL particles in the postprandial
phase. Increased concentrations of in TRL apoE have been observed in hypertriglyceridemia
(Cohn et al. 1996) and type 2 diabetes (Syvänne et al. 1994b), both of which are associated with
defective clearance of postprandial TRL particles. Although postprandial apoE concentration
in chylomicron and VLDL1 fraction increased significantly in smokers, it is possible that the
number of apoE molecules per remnant particle is reduced. However, it is difficult to quantify
the number of apoE per remnant particle. As a rough estimate, we calculated apoB-48 to apoE-
ratio in the chylomicron fraction. In smokers, this ratio was higher at 3 (p = 0.076) and 4 (p =
0.05) hours after the fat intake. Theoretically, relative deficiency of apoE may indicate a
decreased number of ligands per particle and thus impeded hepatic clearance of TRLs. A low
concentration of HDL particles in the postprandial state may serve as a poor donor of apoE or
smoking may induce changes in apoE conformation so that it is less efficiently exchanged or
cleared. Since apoE also appears to play an important role in HDL metabolism and reverse
cholesterol transport (Funke et al. 1984, Koo et al. 1985), these effects might partially explain
the increased risk for the development of cardiovascular disease in smokers. The concept is
supported by studies in apoE knock-out mice, which show increased susceptibility for
atherosclerosis (Plump, et al. 1992).
 
We are unaware of previous studies investigating the effect of smoking on postprandial lipid
transfer activities, which play an important role in the modification of TRL and HDL particles
during the postprandial state (Bruce and Tall 1995). Data on fasting CETP activity levels in
smokers are contradictory. Decreased (De Parscau and Fielding 1986, Freeman et al. 1993),
similar (Freeman, et al. 1998) and increased (Dullaart et al. 1994) CETP activities have been
reported previously. In smokers, CETP activity was reduced through the 8 hour sampling period
compared with control subjects, in whom the activity of CETP remained unchanged. The lower
activity of CETP correlated with total cholesterol concentration, which was reduced in the
smokers. Thus, variations in the CETP activities might reflect differences in total and HDL
cholesterol concentrations and the genetic background of the subjects in these studies. In
smokers, enhanced postprandial TRL response presumably leads to an increased net exchange
of TG and cholesteryl esters between TRL and HDL particles via CETP without increasing its
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activity. This theory is supported by the findings of Mann et al. (1991) and Liinamaa et al.
(1997), who found that in normolipidemic subjects, VLDL concentration determines the rate
of net CE transfer but in hypertriglyceridemia, CETP becomes rate limiting as VLDL
concentration increases.
PLTP levels decreased postprandially in the smokers but not in the controls. Functions of PLTP
in lipoprotein metabolism include transfer of surface fragments, formed during the lipolysis of
TRL, to HDL (Tall, et al. 1985) and conversion of HDL3 to larger HDL2-particles via a process
of fusion (Jauhiainen, et al. 1993, Lusa et al. 1996, Tu, et al. 1993). Therefore, reduced PLTP
activity may lower the concentrations of large buoyant HDL in smokers. The postprandial
decrease in LpA-I (an important component of HDL2) in smokers may, by itself, result in lower
PLTP levels, since PLTP is carried in plasma with large-buoyant HDL (Speijer, et al. 1991).
We also measured PLTP activity dependent on endogenous HDL (see Methods). This value
also decreased postprandially in smokers but not in the controls, thus indicating that not only
PLTP levels but also phospholipid transfer to endogenous HDL is decreased in the postprandial
phase in smokers.
In non-smokers, LCAT activity after an oral fat load has been reported to be stimulated (Rose
and Juliano 1977, Wallentin and Vikrot 1976). However, in control subjects and in smokers,
activities of LCAT were similar both at baseline and in the postprandial state. This finding is
in contradiction with previous in vitro (McCall et al. 1994) and in vivo (Freeman, et al. 1993)
findings of reduction in LCAT activity by smoking. Our smokers abstained from smoking for
at least twelve hours before taking the fat load. Thus it is possible that the effects of smoking
on LCAT may be transient in vivo.
We propose that postprandial lipemia with an increase of apoB-48 concentration in Sf > 60
fractions is a feature of dyslipidemia associated with smoking. Delayed clearance of exogenous
TRL particles is reflected in decreased postprandial HDL cholesterol concentration and changes
in HDL apolipoprotein (apoA-I and apoE) composition. Altered LPL and/or HL functions by
smoking may be important in mediating these changes in the lipoprotein profile. These
variations may be significant because of the direct atherogenic nature of postprandial TRLs
and/or impairment of the reverse cholesterol transport. 
7.4. The effect of lipoprotein lipase Asn291Ser polymorphism on fasting and postprandial
lipid metabolism and insulin sensitivity (Study IV)
In the present study the carriers of LPL Asn291Ser gene variant were selected to have normal
concentrations of fasting TG. Despite that, fasting VLDL1 TG tended to be higher and HDL
cholesterol concentration was lower in carriers than in control subjects with similar sex, age and
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BMI. Previous studies on large number of subjects have shown that the carriers are prone to
dyslipidemia with low HDL cholesterol and high TG concentrations (Jemaa, et al. 1995,
Wittrup, et al. 1997). In the presence of other predisposing factors such as obesity, insulin
resistance, E-4 allele, familial hypercholesterolemia, familial combined hyperlipidemia or
postmenopausal state, fasting dyslipidemia becomes highly prevalent among the carriers (Fisher
et al. 1995, Pimstone et al. 1995, Reymer et al. 1995, Syvänne et al. 1996, Wittrup, et al. 1997,
Zhang et al. 1995).
This study demonstrated delayed postprandial metabolism of TG and retinyl esters, which is
in accordance with a previous study (Pimstone, et al. 1996). The novel finding was that these
changes can be accounted for impaired metabolism of apoB-48 and especially apoB-100
particles in the VLDL1 fraction. A lipolytic defect is the most obvious alternative to explain
the postprandial lipemia in carriers of LPL Asn291Ser gene variant. Carriers displayed not only
a significantly reduced specific activity of LPL but also reduced postheparin LPL activity when
control subjects from Studies II and IV were combined. Furthermore, the activity of LPL was
a determinant of the VLDL1 apoB-48 response in control subjects but not in carriers of
Asn291Ser gene variant, indicating insufficient postprandial lipolytic capacity. Furthermore,
the postprandial differences were discovered mostly in VLDL1 fraction, which consists of
larger TRL particles mostly dependent on LPL action for further processing. Current opinion
is that apoB-48 particles are the preferential substrate for endothelial LPL rather than apoB-100
particles (Björkegren, et al. 1996, Karpe and Hultin 1995). However, we observed increases in
both apoB-48 and apoB-100 concentrations in the VLDL1 fraction. A recent study shows that
the particles preferentially cleared by LPL may vary depending on LPL activity present in
plasma. At low levels (< 120 mU/ mL) of LPL activity apoB-48-containing particles are
lipolyzed more efficiently. When the release of LPL was abundant (> 140 mU/ mL),
comparable percent reductions of apoB-48 and apoB-100 were then observed (Van Beek et al.
1998). Interestingly, the activity of LPL in five carriers was 120 mU/ mL or less, but only two
of the control subjects displayed such low LPL levels. This may represent a mechanism by
which Sf > 60 apoB-100 particles accumulate in carriers of Asn291Ser gene variant.
Insulin regulates the hepatic apoB and VLDL1 production (Malmström, et al. 1997b, Tan et al.
1995) and suppression of hepatic VLDL1 apoB-100 production by insulin appears to be
impaired in insulin resistant subjects (Malmström, et al. 1997a). The carriers and control
subjects displayed similar rates of glucose utilization during insulin infusion, which suggests
that the carriers do not overproduce large VLDL particles due to insulin resistance.
LPL binds to very low density lipoprotein particles and this binding action augments the hepatic
removal of TRL (Skottova, et al. 1995). A recent study demonstrated that catalytically inactive
LPL can act in vivo to mediate VLDL removal from plasma (Merkel, et al. 1998). In vitro
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studies provide evidence that this function is not impaired in the LPL Asn291Ser gene variant
either (Zhang, et al. 1995). Thus, impeded hepatic removal of TRL remnants is an unlikely
cause for postprandial lipemia in the carriers. This concept is indirectly supported by similar
postprandial concentrations of both apoB-48 and apoB-100 particles in VLDL2 (Sf 20-60) and
IDL (Sf 12-20) fractions, forming the major part of TRL remnants.
We observed an increase in TG content of HDL fraction in carriers, which predisposes HDL
particles to hydrolysis by HL resulting in increased proportion of small, dense HDL particles
(Fan et al. 1994) and decreased HDL cholesterol concentration (Patsch, et al. 1992). Low HDL
cholesterol concentration may be a direct consequence of increased postprandial TG
concentrations in normolipidemic carriers of the LPL Asn291Ser gene variant.
Interestingly, gene therapy has been applied for the correction of postprandial lipemia in LPL-
deficient mice. After administration of adenoviruses expressing human LPL, a marked
reduction in fasting VLDL TG and in postprandial lipemia was noted (Excoffon et al. 1997).
This may provide strategies for future prevention of CAD in carriers of the Asn291Ser gene
variant.
7.5. The severity of coronary artery disease and postprandial apolipoprotein B-48 and B-
100 metabolism type 2 diabetes mellitus (Study V)
Alterations in TRL metabolism can be detected already in insulin resistant states, before the
development of type 2 diabetes mellitus (Jeppesen, et al. 1995). Since exaggerated postprandial
lipemia is a key feature of diabetic dyslipidemia, the fundamental question is which TRL
particles contribute to the development of CAD in these subjects. In type 2 diabetic subjects,
studies in postprandial lipoprotein metabolism have mainly included subjects without signs of
CAD (Cavallero, et al. 1994, Chen, et al. 1993, Curtin, et al. 1994, Lewis, et al. 1991).
Previously, one study employed measurement of vitamin A as a marker for intestinal
lipoproteins in diabetic subjects with and without CAD (Syvänne, et al. 1994a). The
postprandial retinyl palmitate response did not, however, separate the two groups. The present
study distinguished between intestinal and hepatic particles by specific determination of apoB-
48 and apoB-100 concentrations and, in agreement with findings of Syvänne et al. (1994a),
postprandial apoB-48 and apoB-100 concentrations did not differ in patients with mild and
severe CAD. 
Type 2 diabetic patients have higher levels of both intestinal and hepatic TRL particles when
compared with healthy non-diabetic males. Diabetic subjects displayed increased TG, apoB-48
and apoB-100 concentrations postprandially in all Sf > 20 fractions, in which TG, apoB-48 and
apoB-100 concentrations rose promptly and remained elevated throughout the 8-hour study
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period. Particles in this size range are capable of penetrating arterial intimal, and are therefore
potentially atherogenic (Nordestgaard 1996, Nordestgaard, et al. 1992). Furthermore, the levels
of both apoB-48 and apoB-100 particles are substantially higher in diabetic subjects compared
with healthy controls even after 12 hours of fasting (Table 5), which emphasizes the 24-hour
predisposition to these atherogenic particles.
In type 2 diabetic subjects, abnormal postprandial TRL metabolism was not modified by the
presence of E-4 allele, an important modulator of postprandial lipemia in non-diabetic subjects
(Bergeron and Havel 1996, Dart et al. 1997) and possibly in diabetic subjects without signs of
CAD (Reznik et al. 1996). Obviously the effect of minor determinants of TRL metabolism,
including apoE-4 allele, do not further aggravate the postprandial response in type 2 diabetic
subjects with signs of CAD.
The severity of coronary atherosclerosis, however, correlated with postprandial change of apoB-
100 concentration in the IDL (Sf 12-20) fraction. Thus, the subjects with a greater decline in
postprandial IDL particle numbers had milder occlusion of coronary vessels. Recently, in a
study by Tkác et al. (1997), fasting TRL apoB, especially in Sf 12-60 fraction, was significantly
higher in diabetic subjects with moderate and severe CAD compared with those exhibiting mild
CAD. The coronary score correlated with TRL apoB concentration. Interestingly, no differences
in any lipid parameter between the groups with moderate and severe CAD could be detected.
The authors concluded that the severity of CAD in diabetic patients was positively related to
the number of fasting TRL particles (Tkác, et al. 1997). Accordingly, the present finding may
provide evidence for the significance of postprandial small TRLs in the development of
atherosclerosis in type 2 diabetes. 
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8. SUMMARY AND CONCLUSIONS
1. In normolipidemic men, the postprandial responses of TG, apoB-48, apoB-100 and apoE in
TRL fractions were similar after an oral fat load containing either soybean oil or saturated fat.
Furthermore, after the fat loads exchange of TG and cholesterol between TRL and HDL
fractions resulted in comparable postprandial HDL concentrations and composition. The use
of vitamin A administration to label intestinal TRL particles appeared, however, questionable,
since retinyl ester responses differed from those of apoB-48 and TG in TRL fractions after
soybean oil fat load.
 
2. Compared with non-smokers,  smokers displayed lipid intolerance due to impaired
postprandial metabolism of apoB-48 particles in the chylomicron, VLDL1 and VLDL2
fractions. The responses of TG and retinyl esters paralleled that of apoB-48. Adjustment for
confounding factors did not affect the study outcome. The findings imply that in
normolipidemic smokers, the increased levels of postprandial TRL remnants may predispose
for the development of CAD. 
3. Concurrently with postprandial increase of apoB-48 particles in TRL fractions, smokers
exhibited a decline in postprandial HDL cholesterol concentration. Reduction of HDL-
associated apolipoproteins, apoA-I and apoE, suggest alterations in HDL composition during
postprandial lipemia. Smoking modified postprandial PLTP activity and esterification rate, but
not LCAT or CETP activities. Thus, postprandial lipemia in smokers may impair reverse
cholesterol transport and promote atherogenesis. 
4. Carriers of the LPL Asn291Ser gene variant with normal insulin sensitivity and fasting lipid
concentrations showed defective metabolism of apoB-48 and particularly apoB-100 particles
in the VLDL1 fraction. Subnormal LPL activity and reduced specific activity of LPL suggest
saturation of the common lipolytic pathway as a cause for postprandial lipemia. The
accumulation of large VLDL particles results in increased exchange of core lipids, and thus in
decreased HDL cholesterol concentration and altered HDL composition both in fasting and
postprandial states. Postprandial lipemia may present a mechanism which favors development
of CAD in normolipidemic carriers of the Asn291Ser gene variant.
5. Fasting and postprandial dyslipidemia in type 2 diabetes mellitus comprises high levels of
both apoB-48 and apoB-100 particles in the chylomicron and VLDL1 fractions. The degree of
postprandial lipemia, however, was not modulated by the presence of apoE-4 allele or by the
extent of coronary atherosclerosis determined by quantitative coronary angiography. The most
severe stenosis in coronary angiography correlated with postprandial change in number of small
apoB-100 remnant particles, the high level of which may favour the progression of CAD in type
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2 diabetic patients.
In summary, present studies have provided clinical evidence that smoking and presence of LPL
Asn291Ser gene variant may disturb postprandial lipid metabolism before occurrence of fasting
dyslipidemia. Postprandial TRL particles are capable of penetrating arterial intima in vitro, and
furthermore, these particles induce formation of foam cells. Therefore, in smokers and in
heterozygous carriers of LPL Asn291Ser gene variant, postprandial TRL particles may
contribute to the early development of atherosclerosis. In type 2 diabetic patients, elevated
levels of both intestinal and hepatic TRL are present in subjects with mild and severe
angiographic CAD. Postprandial lipemia presents an inherent feature of diabetic dyslipidemia,
which most probably arise in prediabetic insulin resistant states. In future, both prospective
clinical studies and basic metabolic research are required to ultimately summarize the role of
TRL particles in development and progression of CAD.
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